

Identification of cyclobutane pyrimidine dimer-responsive genes using UVB-irradiated human keratinocytes transfected with in vitro-synthesized photolyase mRNA

--Manuscript Draft--

Manuscript Number:	PONE-D-15-07621R1
Article Type:	Research Article
Full Title:	Identification of cyclobutane pyrimidine dimer-responsive genes using UVB-irradiated human keratinocytes transfected with in vitro-synthesized photolyase mRNA
Short Title:	Characterization of CPD-responsive transcriptional changes
Corresponding Author:	Gábor Boros University of Debrecen Debrecen, HUNGARY
Keywords:	pseudouridine-modified mRNA; cyclobutane pyrimidine dimers; photolyase; UVB; transcriptional changes; human keratinocytes
Abstract:	Major biological effects of UVB are attributed to cyclobutane pyrimidine dimers (CPDs), the most common photolesions formed on DNA. To investigate the contribution of CPDs to UVB-induced changes of gene expression, a model system was established by transfecting keratinocytes with pseudouridine-modified mRNA (Ψ-mRNA) encoding CPD-photolyase. Microarray analyses of this model system demonstrated that more than 50% of the gene expression altered by UVB was mediated by CPD photolesions. Functional classification of the gene targets revealed strong effects of CPDs on the regulation of the cell cycle and transcriptional machineries. To confirm the microarray data, cell cycle-regulatory genes, CCNE1 and CDKN2B that were induced exclusively by CPDs were selected for further investigation. Following UVB irradiation, expression of these genes increased significantly at both mRNA and protein levels, but not in cells transfected with CPD-photolyase Ψ-mRNA and exposed to photoreactivating light. Treatment of cells with inhibitors of c-Jun N-terminal kinase (JNK) blocked the UVB-dependent upregulation of both genes suggesting a role for JNK in relaying the signal of UVB-induced CPDs into transcriptional responses. Thus, photolyase mRNA-based experimental platform demonstrates CPD-dependent and -independent events of UVB-induced cellular responses, and, as such, has the potential to identify novel molecular targets for treatment of UVB-mediated skin diseases.
Order of Authors:	Gábor Boros Edit Miko Hiromi Muramatsu Drew Weissman Eszter Emri Gijsbertus van der Horst Andrea Szegedi Iréen Horkay Gabriella Emri Katalin Karikó Éva Remenyik
Opposed Reviewers:	Carlos Menck University of Sao Paulo cfmmenck@usp.br Photolyase expert. Peter Wolf Medical University of Graz peter.wolf@medunigraz.at

	<p>Dermatological research expert.</p> <p>Neil Gibbs University of Manchester Medical School Neil.K.Gibbs@manchester.ac.uk DNA damage expert.</p> <p>Leon Mullenders Leiden University Medical Center l.mullenders@lumc.nl UV damage repair expert.</p>
Response to Reviewers:	<p>Responses to the comments of Reviewer 1</p> <p>Dear Reviewer,</p> <p>Thank you for your thoughtful and constructive comments.</p> <p>We addressed all your comments and further experimentation was performed, according to your advice.</p> <p>Specifically:</p> <p>Comment 1. The paper would be much strengthened by further experiments directly addressing JNK in mediating CPD effects (e.g. inhibit JNK and then determine photolyase effect with and without UV), without this critical experiment, the manuscript is, in my opinion, too correlative.</p> <p>We agree with your assertion and carried out the proposed experiment. The results are included into the revised Figure 4 (see lines 330-340, on page 15 of the revised manuscript).</p> <p>Comment 2. Is it possible that certain genes (e.g. their promoters or enhancers) may be particularly vulnerable to UV-induced CPD formation? If so, then these genes may be down-regulated directly by UV rather than through a damage-response pathway such as JNK. (alternatively a gene's expression might be upregulated if an inhibitory gene's expression were CPD-prone).</p> <p>We agree that regulatory regions of selected genes might be directly vulnerable to UVB, therefore we included this potential in the manuscript and added background material to the revised manuscript and propounded an experimental procedure to appropriately support this issue (see lines 483-491, on pages 21-22 of the revised manuscript).</p> <p>Comment 3. It seems odd that the figure legends are embedded right in the text rather than as a separate section.</p> <p>We corrected this error. The figure legends are now in a separate section at the end of the revised manuscript.</p> <p>Comment 4. Do the data exclude a role for gene regulation by 6,4-photoproducts?</p> <p>We have added a new section to the revised manuscript in which we provide additional information related to the contribution of 6-4 photoproducts to UVB-induced changes of gene expression (see lines 368-379, on page 17 of the revised manuscript).</p> <p>Comment 5. The role of p53 should also be examined in CPD-induced gene expression changes.</p> <p>We agree, so we have inserted background material to provide additional information about the role of p53 in UVB-induced cellular stress responses (see lines 395-404, on page 18 of the revised manuscript).</p> <p>Response to the comment of Reviewer 2</p> <p>Dear Reviewer,</p> <p>We appreciate your comment and following your suggestion we prepared a separate conclusion section.</p> <p>Comment 1. The major short-coming, which is mostly editorial, is coming from the lack of a separate conclusion section. The last paragraph, which effectively serves as a conclusion, needs to be expanded and be placed in line with the abstract.</p> <p>We have added a separate conclusion section to provide additional context to the revised manuscript (see lines 493-511, on page 22 of the revised manuscript).</p>
Additional Information:	
Question	Response
Financial Disclosure	<p>This work was supported by National Institutes of Health (grant number R01NS029331 and R42HL87688 to K.K.; R01AI50484 and R21DE019059 to D.W.), the Hungarian Scientific Research Fund (OTKA K105872 to É.R., OTKA K108421 to A.SZ.) and National Research Grant (TÁMOP-4.2.2-A-11/1/KONV-2012-0031 to É.R.).</p>
Please describe all sources of funding	The funders had no role in study design, data collection and analysis, decision to

<p>that have supported your work. A complete funding statement should do the following:</p> <p>Include grant numbers and the URLs of any funder's website. Use the full name, not acronyms, of funding institutions, and use initials to identify authors who received the funding.</p> <p>Describe the role of any sponsors or funders in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. If they had <u>no role</u> in any of the above, include this sentence at the end of your statement: <i>"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</i></p> <p>If the study was unfunded, provide a statement that clearly indicates this, for example: <i>"The author(s) received no specific funding for this work."</i></p> <p>* typeset</p>	<p>publish, or preparation of the manuscript."</p>
<p>Competing Interests</p> <p>You are responsible for recognizing and disclosing on behalf of all authors any competing interest that could be perceived to bias their work, acknowledging all financial support and any other relevant financial or non-financial competing interests.</p> <p>Do any authors of this manuscript have competing interests (as described in the PLOS Policy on Declaration and Evaluation of Competing Interests)?</p> <p>If yes, please provide details about any and all competing interests in the box below. Your response should begin with this statement: <i>I have read the journal's policy and the authors of this manuscript have the following competing interests:</i></p> <p>If no authors have any competing interests to declare, please enter this statement in the box: <i>"The authors have declared that no competing interests exist."</i></p>	<p>I have read the journal's policy and the authors of this manuscript have the following competing interests: Katalin Karikó and Drew Weissman hold patents for the use of nucleoside-modified mRNA as a therapeutic protein delivery platform. They have also formed a small biotech company, RNARx, that received funding from the National Institutes of Health (R42HL87688) to explore the use of nucleoside-modified mRNA for transient gene therapy.</p>

* typeset

Ethics Statement

N/A

You must provide an ethics statement if your study involved human participants, specimens or tissue samples, or vertebrate animals, embryos or tissues. All information entered here should **also be included in the Methods section** of your manuscript. Please write "N/A" if your study does not require an ethics statement.

Human Subject Research (involved human participants and/or tissue)

All research involving human participants must have been approved by the authors' Institutional Review Board (IRB) or an equivalent committee, and all clinical investigation must have been conducted according to the principles expressed in the [Declaration of Helsinki](#). Informed consent, written or oral, should also have been obtained from the participants. If no consent was given, the reason must be explained (e.g. the data were analyzed anonymously) and reported. The form of consent (written/oral), or reason for lack of consent, should be indicated in the Methods section of your manuscript.

Please enter the name of the IRB or Ethics Committee that approved this study in the space below. Include the approval number and/or a statement indicating approval of this research.

Animal Research (involved vertebrate animals, embryos or tissues)

All animal work must have been conducted according to relevant national and international guidelines. If your study involved non-human primates, you must provide details regarding animal welfare and steps taken to ameliorate suffering; this is in accordance with the recommendations of the Weatherall report, "[The use of non-human primates in research](#)." The relevant guidelines followed and the committee that approved the study should be identified in the ethics statement.

<p>If anesthesia, euthanasia or any kind of animal sacrifice is part of the study, please include briefly in your statement which substances and/or methods were applied.</p> <p>Please enter the name of your Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board, and indicate whether they approved this research or granted a formal waiver of ethical approval. Also include an approval number if one was obtained.</p> <p>Field Permit</p> <p>Please indicate the name of the institution or the relevant body that granted permission.</p>	
<p>Data Availability</p> <p>PLOS journals require authors to make all data underlying the findings described in their manuscript fully available, without restriction and from the time of publication, with only rare exceptions to address legal and ethical concerns (see the PLOS Data Policy and FAQ for further details). When submitting a manuscript, authors must provide a Data Availability Statement that describes where the data underlying their manuscript can be found.</p> <p>Your answers to the following constitute your statement about data availability and will be included with the article in the event of publication. Please note that simply stating 'data available on request from the author' is not acceptable. If, however, your data are only available upon request from the author(s), you must answer "No" to the first question below, and explain your exceptional situation in the text box provided.</p> <p>Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?</p>	<p>Yes - all data are fully available without restriction</p>
<p>Please describe where your data may be found, writing in full sentences. Your answers should be entered into the box below and will be published in the form you provide them, if your manuscript is accepted. If you are copying our sample text below, please ensure you replace any instances of XXX with the appropriate</p>	<p>All relevant data are within the paper and its Supporting Information files.</p>

<div>details.</div> <div>If your data are all contained within the paper and/or Supporting Information files, please state this in your answer below. For example, "All relevant data are within the paper and its Supporting Information files."</div> <div>If your data are held or will be held in a public repository, include URLs, accession numbers or DOIs. For example, "All XXX files are available from the XXX database (accession number(s) XXX, XXX)." If this information will only be available after acceptance, please indicate this by ticking the box below. If neither of these applies but you are able to provide details of access elsewhere, with or without limitations, please do so in the box below. For example:</div> <div>"Data are available from the XXX Institutional Data Access / Ethics Committee for researchers who meet the criteria for access to confidential data."</div> <div>"Data are from the XXX study whose authors may be contacted at XXX."</div> <div>* typeset</div>	
Additional data availability information:	

Dr. Mauro Picardo
The Editor
PLOS ONE

19/05/2014

Dear Professor Picardo,

Thank you for reviewing our manuscript "*Identification of cyclobutane pyrimidine dimer-responsive genes using UVB-irradiated human keratinocytes transfected with in vitro-synthesized photolyase mRNA*" (Manuscript ID PONE-D-15-07621) and for the opportunity to submit a revised manuscript for further peer review.

We are very grateful for your evaluating of our paper. We addressed all the comments of the reviewers and performed additional experiments. A separate conclusion section has been prepared as requested by Reviewer 2. The new text is underlined and highlighted in yellow while the crossed-out text refers to the deleted original text.

Hereby, we submit the revised manuscript and looking forward to your response.

We hope that the revised manuscript will meet the expectations of the reviewers and the high standards of PLOS ONE.

We approve Competing Interests statement proposed by editorial manager of PLOS ONE.

We confirm that Katalin Kariko and Hiromi Muramatsu moved to Biontech RNA Pharmaceuticals GmbH, Mainz, Germany after they performed their major role in the study at the U. Pennsylvania. Their contribution subsequently was to help to write the manuscript. They performed this task during their spare time off from work.

"This work was supported by National Institutes of Health (grant number R01NS029331 and R42HL87688 to K.K.; R01AI50484 and R21DE019059 to D.W.), the Hungarian Scientific Research Fund (OTKA K105872 to É.R., OTKA K108421 to A.S.) and National Research Grant (TÁMOP-4.2.2-A-11/1/KONV-2012-0031 to É.R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

Yours sincerely,
Gabriella Emri, M.D., Ph.D.
Department of Dermatology
University of Debrecen
Nagyterdei korut 98
4032 Debrecen
Hungary
phone: +36 30 437 4672
e-mail: gemri@med.unideb.hu

Identification of cyclobutane pyrimidine dimer-responsive genes using UVB-irradiated human keratinocytes transfected with *in vitro*-synthesized photolyase mRNA

Gábor Boros¹, Edit Miko^{1,#a}, Hiromi Muramatsu^{2,#b}, Drew Weissman³, Eszter Emri¹,
Gijbertus T.J. van der Horst⁴, Andrea Szegedi^{1,5}, Irén Horkay¹, Gabriella Emri^{1,*}, Katalin
Karikó^{2,#b}, Éva Remenyik¹

¹Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen,
Hungary

²Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania,
United States of America

³Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United
States of America

⁴Department of Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.

⁵Department of Dermatological Allergology, Faculty of Medicine, University of Debrecen,
Debrecen, Hungary

*Corresponding author

E-mail: gemri@med.unideb.hu (GE)

^{#a} Current affiliation: MTA-DE Lendület Laboratory of Cellular Metabolism Research Group
of the Hungarian Academy of Sciences, Debrecen, Hungary

^{#b} Current affiliation: BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany

Abstract

Major biological effects of UVB are attributed to cyclobutane pyrimidine dimers (CPDs), the most common photolesions formed on DNA. To investigate the contribution of CPDs to UVB-induced changes of gene expression, a model system was established by transfecting keratinocytes with pseudouridine-modified mRNA (Ψ -mRNA) encoding CPD-photolyase. Microarray analyses of this model system demonstrated that more than 50% of the gene expression altered by UVB was mediated by CPD photolesions. Functional classification of the gene targets revealed strong effects of CPDs on the regulation of the cell cycle and transcriptional machineries. To confirm the microarray data, cell cycle-regulatory genes, *CCNE1* and *CDKN2B* that were induced exclusively by CPDs were selected for further investigation. Following UVB irradiation, expression of these genes increased significantly at both mRNA and protein levels, but not in cells transfected with CPD-photolyase Ψ -mRNA and exposed to photoreactivating light. Treatment of cells with inhibitors of c-Jun N-terminal kinase (JNK) blocked the UVB-dependent upregulation of both genes suggesting a role for JNK in relaying the signal of UVB-induced CPDs into transcriptional responses. Thus, photolyase mRNA-based experimental platform demonstrates CPD-dependent and -independent events of UVB-induced cellular responses, and, as such, has the potential to identify novel molecular targets for treatment of UVB-mediated skin diseases.

Introduction

The incidence of keratinocyte-derived skin cancer, which is the most common human malignancy, continues to increase worldwide, thus presenting a serious challenge to healthcare systems [1]. Ultraviolet B (UVB) (290-320 nm) radiation is the main environmental risk factor for sunburn, skin carcinogenesis and premature skin ageing [2,3]. Cyclobutane pyrimidine dimers (CPDs) are the predominant photolesions caused by UVB radiation, and primarily they are responsible for these adverse effects [4]. CPDs are the most deleterious and premutagenic photolesions, due to their ability to distort the structure of the DNA, leading to disturbance of DNA replication and transcription [5,6]. The pathogenetic role of CPDs is further substantiated by presence of CPD-related signature mutations in genes involved in the formation of skin cancers [7], as well as, by the correlation between the action spectrum value for the induction of CPD photolesions and development of UV-induced skin cancer in animal models [8,9]. In addition, CPDs have been shown to mediate UVB-induced erythema [10] and immunosuppression [11,12]. Naturally, DNA lesions, including CPDs are excised by the nucleotide excision repair (NER) system of human keratinocytes [13]. However, the rate and accuracy of DNA repair by NER are suboptimal [14].

CPD-photolyase is a structure-specific DNA repair enzyme that specifically binds and cleaves CPDs using the energy of visible light ("photoreactivation"), thereby simply and rapidly restoring DNA integrity [15]. This enzyme functions in diverse organisms from bacteria to vertebrates but is absent in placental mammals, including humans, that must rely solely on the less potent NER to repair UV-induced DNA lesions [16]. Sunscreen lotions containing liposomal-encapsulated bacterial photolyase or CPD-specific endonuclease have been marketed for preventing UV-induced skin damages [17], especially in patients with NER-deficiency [18].

In a previous study, we applied a novel mRNA-based gene delivery method, and demonstrated that transfection of pseudouridine-modified mRNA (Ψ -mRNA) encoding *Potorous tridactylus* CPD-photolyase (CPD-PL) into human keratinocytes leads to rapid repair of DNA-damage [19]. Pseudouridine modifications increase mRNA stability [20], make it highly translatable [21,22] and abolish immunogenicity of the RNA [23]. It is well documented that CPD lesions are considered to be the principal mediator of UV-induced mutagenesis and DNA double-strand break (DSB) signalling [7,9]. However, so far, it has been unclear how CPDs change gene expression and cell activities. To gain insight, we performed a global analysis (microarray) of molecular networks. Most dermatological studies, in which microarray technology was used, analysed differential expression of genes comparing normal and pathologic skin samples in order to identify genes associated with a specific skin condition or with tumor progression [24-28]. Microarray platforms were also used to identify UV-regulated genes and have uncovered that significant change in the expression profiles of hundreds of genes are induced by UV. Altered expression of genes in response to UV irradiation have been determined in epidermal keratinocytes [29], fibroblasts [30] and melanocytes [31]. Microarray experiments have demonstrated that UVB exposure affects several biological processes indicating the complexity of UV-induced cellular activities. Studies performed on human keratinocytes identified UVB-induced genes that were involved in proteasome-mediated pathways, cytoskeleton organization, cell cycle and apoptosis networks, and control of basal transcription and translation leading to inhibition of cell growth [29,32-34]. Furthermore, it has been shown that the repair rate of DNA lesions alters the UV-induced transcription profile, thus suggesting that adequate removal of the photoproducts could avoid UV-related cutaneous pathologies [35]. However, until now, there was no suitable experimental platform to identify directly CPD-responsive genes in human cells, thus distinguish CPD-regulated cellular mechanisms from those mediated by other

UVB-induced derivatives, including diverse photoproducts, reactive oxygen species, cross-linked protein-DNA and other damaged macromolecules.

Here, we present data obtained by using human keratinocytes transfected with *in vitro*-synthesized nucleoside-modified mRNA encoding a marsupial-specific CPD-photolyase. This model system enabled us to distinguish between CPD-dependent and -independent cellular processes. We determined the UVB-induced transcriptional responses in human keratinocytes using the combination of a CPD-specific photolyase Ψ -mRNA delivery with a genomics approach. Pathway analysis revealed a strong effect of CPDs on the expression levels of genes involved in the control of the cell cycle and transcriptional machineries. Our findings demonstrate that the c-Jun N-terminal kinase (JNK) signalling pathway plays a role in conversion of the cues generated by UVB-induced CPDs into a transcriptional response.

Materials and Methods

RNA synthesis

Messenger RNAs were generated as previously described [19], using linearized plasmids (pTEV-CPD-PL-A101 and pTEVeGFP-A101) encoding codon-optimized *Potorous* CPD-photolyase (CPD-PL Ψ -mRNA) and enhanced green fluorescent protein (eGFP Ψ -mRNA). The CPD-photolyase gene from *Potorous tridactylus* (rat kangaroo) was synthesized by Entelechon (Bad Abbach, Germany). The Megascript T7 RNA polymerase kit (Ambion, Austin, TX) was used for transcription, and UTP was replaced with pseudouridine triphosphate (TriLink, San Diego, CA) [21]. To remove the template DNA Turbo DNase (Ambion) was added to the reaction mix. Pseudouridine-modified mRNAs were HPLC-purified as described [36] and provided with cap1 generated by using the m7G capping enzyme and 2'-O-methyltransferase according to the manufacturer (CellScript, Madison, WI).

The mRNAs were transcribed to contain 101 nt-long 3' poly(A) tail. Small aliquots of RNA samples were stored in siliconized tubes at -20°C .

Keratinocyte cell line

An established HaCaT cell line [37] was maintained in high glucose DMEM (Lonza, Verviers, Belgium) supplemented with 2 mM L-glutamine (Lonza), 10% fetal bovine serum (Lonza) and 0.5% antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA) at 37°C with 5% CO_2 .

Transient transfection and treatments

Transient transfection of Ψ -mRNA into HaCaT cells, UVB exposure and photoreactivation experiments were carried out, as previously described [19], except that a ratio of mRNA (0.25 μg) and Lipofectamine LTX-PLUS (Life Technologies) reagent (1.0 μl) in a final volume of 100 μl EpiLife keratinocyte growth medium (Life Technologies, Carlsbad, CA, USA) was used. Following a two-hour transfection, the lipofectamine-RNA complex was replaced with 100 μl fresh culture medium. At 12 h post transfection, the cell monolayer in a well of a 96-well plate, was covered with 50 μl Dulbecco's phosphate buffer saline (Life Technologies) and subjected to 20 mJ/cm^2 UVB using two TL-20W/12 tubes (Philips). Proper dosage of UVB was determined by a UVX Digital Radiometer (UVP Inc., San Gabriel, CA, USA). Immediately after UVB treatment, cells were exposed to visible light ("photoreactivation") using F18W Daylight fluorescent tubes (Sylvania) or kept in the dark for one hour. At 5 and 23 h following photoreactivation, total RNA and genomic DNA were isolated from the cells.

Enzyme-linked immunosorbent assay (ELISA)

Genomic DNA was extracted from HaCaT cell line using the Qiagen Blood and Cell Culture kit (Qiagen, Hilden, Germany), according to the manufacturer. A direct ELISA was applied

for detection of CPD, as previously described [19]. Anti-CPD monoclonal antibody (TDM-2, Cosmo Bio, Tokyo, Japan) diluted in PBS (1:1000) was used as primary antibody.

Microarray analysis

Total RNA was isolated from HaCaT cells using Trizol reagent (MRC, Cincinnati, OH, USA), according to the manufacturer's instructions. RNA samples were treated by DNase I (Fermentas, St. Leon-Rot, Germany) and their quality were analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Gene expression profiling of HaCaT cells transfected with CPD-photolyase mRNA was performed using a service provider (ChromoScience, Budapest, Hungary, <http://www.chromoscience.hu>). Briefly, cyanine 3-labeled cRNA was synthesized from 200 ng total RNA by the QuickAmp Labeling Kit (Agilent Technologies), according to the manufacturer. For each sample, 1650 ng of one-color labeled cRNA was hybridized to an Agilent 4x44 K Whole Human Genome Oligo (Agilent Technologies) microarray platform at 65°C for 17 h. All further steps were carried out according to the manufacturer (Agilent Technologies). The slides were scanned with the Agilent Microarray Scanner. Data were then normalized by the Feature Extraction software version 9.5 (Agilent Technologies) with default settings for one-color oligonucleotide microarrays and then transferred to GeneSpringGX program (Agilent Technologies) for further statistical evaluation. In GeneSpring, the normalization and data transformation steps recommended by Agilent Technologies for one-color data were applied at each time point. Microarray data have been submitted to Gene Expression Omnibus (GEO) [38] database and can be retrieved at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65034> (GEO Series accession number: GSE65034). Three replicates of the following 3 types of CPD-PL Ψ -mRNA transfected samples were studied by the microarray: non-irradiated, UVB-irradiated without photoreactivating light (inactive CPD-photolyase), UVB-irradiated plus photoreactivated (active CPD-photolyase). Genes showing statistically significant 2-fold

change were selected for further study by Ingenuity Pathway Analysis (IPA, Qiagen; <http://www.ingenuity.com/products/ipa>) and Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov>) gene functional classification tool.

Real-time quantitative RT-PCR analysis

To validate the microarray data, real-time quantitative reverse transcription (RT)-PCR was used. RT was performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), according to the manufacturer. RT reactions contained 500-500 ng of RNA. To quantitate the expression of candidate genes, the following TaqMan Gene Expression assays (Life Technologies) were used: *ATF3* (Hs00231069_m1), *CCNE1* (Hs01026536_m1), *CDKN2B* (p15INK4b) (Hs00793225_m1), *EGR1* (Hs00152928_m1), *ID2* (Hs04187239_m1), *PTGS2* (*COX-2*) (Hs00153133_m1), *RUNX1* (Hs00231079_m1), *SNAI2* (Hs00950344_m1), the sequences are proprietary and not released by the company. To determine mRNA expression of *SNAI1* the following custom-designed primers and probe set were used: Forward primer: 5'-ACT ATG CCG CGC TCT TTC-3'; Reverse primer: 5'-GCT GGA AGG TAA ACT CTG GAT-3'; and the probe sequence is: 5'-[6-carboxyfluorescein (FAM)] AAT CGG AAG CCT AAC TAC AGC GAG C [tetramethylrhodamine (TAMRA)]-3'. The composition of RT mixes, the PCR reactions and the RT-PCR protocols were carried out as previously described [19] using the ABI 7900 HT Sequence Detection System (Life Technologies). Relative RNA expression values were calculated using the $2^{-\Delta\Delta C_t}$ method [39] in which expression levels in samples containing active CPD-photolyase were compared to those containing inactive one. *SDHA* (Hs00188166_m1) and *PGK1* (Hs00943178_g1) mRNA levels that showed the smallest variation upon UVB exposure in keratinocytes [40] were used for normalization.

Western blot analysis

For Western blot analyses, whole cell extracts were prepared, as previously described [19]. Proteins (10 µg) were separated on 12% polyacrylamide gels and transferred to nitrocellulose membranes (BioRad, Berkeley, CA, USA). After blocking the membranes in 5% non-fat dry milk, the membranes were incubated with primary antibodies diluted (1:750) in 5% skimmed milk at 4°C overnight, then with the appropriate secondary antibodies (1:3000) at room temperature for 1 hour. The following primary antibodies were used: anti-CCNE1 (4129), anti-β-actin (3700) (Cell Signaling Technology, Danvers, MA, USA) and anti-CDKN2B (p15INK4b) (MA1-12294, Thermo Fisher Scientific, Rockford, IL, USA). Goat anti-mouse or anti-rabbit IgG conjugated with horseradish peroxidase (HRP) was used as a secondary antibody (BioRad). The visualization of proteins was achieved with ECL Prime Western blotting detection system (GE Healthcare, Little Chalfont, UK) and densitometry was performed using ImageJ public software (NIH, Bethesda, MD, USA).

Inhibitor treatment

Keratinocytes at 85% confluency were transfected with lipofectamine-complexed CPD-PL Ψ-mRNA. Twelve hours later, cells were pretreated with specific inhibitors of JNK (SP600125), p38 MAPK (SB203580) or AKT (MK-2206) at a final concentration of 40 µM, 10 µM and 10 µM, respectively for 1 hour before treatment with UVB and subsequent photoreactivation. All chemical agents were purchased from SelleckChem (Selleck Chemicals, Houston, TX, USA) and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Stock solutions were prepared according to the manufacturer and stored at -20°C.

Statistical evaluation

Identification of genes differentially expressed in microarray experiments was carried out by the unpaired, Student's *t*-test followed by Benjamini-Hochberg correction. Statistical analysis of qRT-PCR data was performed using GraphPad Prism 5 software (GraphPad Software Inc.,

San Diego, CA, USA). The significance of differences in terms of mRNA expression comparing UVB-irradiated samples to non-irradiated ones, or UVB-irradiated plus photoreactivated (active CPD-photolyase) samples to non-photoreactivated (inactive CPD-photolyase) samples, respectively, was determined by the two-tailed, unpaired *t*-test. A *p* value of equal to or less than 0.05 was considered statistically significant.

Results

Accelerated removal of CPD lesions in keratinocytes transfected with CPD-photolyase mRNA

To test the enzymatic activity of CPD-photolyase translated in HaCaT cells from the transfected mRNA (CPD-PL Ψ -mRNA), cells were subjected to a physiological dose of UVB (20 mJ/cm²) 12 h after transfection of lipofectamine-complexed CPD-PL Ψ -mRNA. Immediately thereafter, cells were either exposed to photoreactivating light, or left in the dark for 1 hour. Cells were harvested 5 and 23 hours later, and CPD-specific ELISA was performed to measure the amount of CPDs formed in genomic DNA. The amount of CPDs in CPD-PL Ψ -mRNA transfected cells was reduced by 90% in those receiving photoreactivating light (photoreactivated), as compared to cells kept in the dark (non-photoreactivated) (Fig. 1). Cells transfected with control eGFP Ψ -mRNA contained the highest amount of CPD lesions at both 6 and 24 h after UVB irradiation (Fig. 1). A reduced amount of CPD lesions were measured in all irradiated samples at 24 h vs. at 6 h due to slower endogenous NER-mediated DNA repair.

CPD-dependent changes were distinguished within the UVB-induced alterations of gene expression in human keratinocytes

To determine the CPD-dependent gene expression profile of human keratinocytes exposed to

UVB irradiation, an oligonucleotide-based DNA microarray analysis was performed in which HaCaT cells transfected with CPD-PL Ψ -mRNA were used. Total RNA was isolated at 6 and 24 h after UVB exposure and subsequent photoreactivation (or not). Gene expression values of UVB-irradiated plus photoreactivated samples (active CPD-photolyase) were compared to non-irradiated samples and to those that were UVB irradiated, but left without photoreactivation (inactive CPD-photolyase). UVB irradiated, but non-photoreactivated samples were also compared to non-irradiated samples. Cut-off values for changes in gene expression were set at ± 2 -fold, and according to this criterion, expression levels of 2,370 out of 41,000 genes were changed at 6 or 24 h after UVB exposure. Altered expression of 1,334 (56%) of UVB-regulated genes was restored in cells that contained active CPD-photolyase indicating that the changes in the expression of these genes were CPD-dependent (S1 Fig.). Importantly, more CPD-dependent gene expression changes (1,008 out of 1,334 genes) were observed at 6 h vs. 24 h, potentially due to the higher difference in CPD levels at 6 h comparing cells with active CPD-photolyase to those with inactive one (S1 Fig., S1 and S2 Tables). There are other reasons, such as transient expression of induced genes. On the other hand, CPD-dependent genes represented more than half of the UVB-regulated genes (1008 out of 1743 genes and 326 out of 627 genes at 6 and 24 h after UVB irradiation, respectively) at both time points after the exposure (S1 Fig., S1 and S2 Tables). These data suggest that UVB-induced CPDs mediate a significant portion of the transcriptional alterations after 6 and 24 hours in response to UVB irradiation of human keratinocytes.

UVB-induced, CPD-dependent genes are associated with cellular stress responses

To determine possible network interactions and associated biological functions of CPD-regulated genes, datasets representing all the differentially expressed genes derived from

255 microarray analyses were imported into IPA and DAVID software. Using these applications,
 256 we determined that a majority of CPD-dependent genes at 6 h after UVB exposure belong to
 257 the regulatory network of *Cell Cycle and Gene Expression*, while those at the 24 h belong to
 258 the network of *Cellular Development, Growth and Proliferation* (S2A Fig., S3A-S3G Fig.).
 259 The top-rated network of CPD-regulated genes at 6 h after UVB irradiation was centered
 260 around a proto-oncogene (*c-Jun*); the prostaglandin-endoperoxide synthase 2 (*PTGS2*), which
 261 is a major mediator of inflammation, and the glucocorticoid receptor (*NR3C1*), which mainly
 262 functions as a transcription factor (S2B Fig.). In addition, c-Jun and interleukin 6 (*IL6*), the
 263 transcriptional regulator nuclear factor kappa B (*NF-κB*), *p38* and the protein kinase *ERK*
 264 were central nodes in the top network of CPD-dependent genes at 24 h after UVB exposure
 265 (S2C Fig.). 122 out of the 1008 CPD-regulated genes belonged to the best-scored IPA
 266 network at 6 h after UVB and 60 out of the 326 CPD-regulated genes at 24 h after the
 267 exposure (S2A Fig.). Functional classification of CPD-regulated genes within networks (S2B-
 268 S2C Fig.) suggested that a wide range of cell cycle-regulatory genes, positive or negative
 269 regulators of the transcriptional and cell recovery machineries, proto-oncogenes, apoptosis
 270 and protein kinase related genes were uniquely induced or repressed by CPD photolesions
 271 (S3A-S3G Fig.). Nine genes regulated by CPDs were selected for further investigation based
 272 on the microarray data and their involvement in cell cycle regulation (*CCNE1*, *CDKN2B*),
 273 transcriptional regulation (*ATF3*, *EGRI*, *ID2*, *RUNX1*), epithelial to mesenchymal transition
 274 (*SNAI1*, *SNAI2*) and inflammation (*PTGS2*) (Table 1).

Table 1. Summarized fold change values by microarray results of the selected 9 CPD-dependent genes.

GenBank ID	Gene	Description	6 h after UVB irradiation		24 h after UVB irradiation	
			vs non-irradiated	active PL vs inactive PL	vs non-irradiated	active PL vs inactive PL
NM_001040619	ATF3	activating transcription factor 3	5.65	-3.30	1.85	-1.90
NM_001238	CCNE1	cyclin E1	2.87	-2.14	1.17	1.13
NM_004936	CDKN2B	cyclin-dependent kinase inhibitor 2B	7.76	-3.36	2.05	-2.06
NM_001964	EGR1	early growth response 1	2.51	-3.95	3.38	-2.39
NM_002166	ID2	inhibitor of DNA binding 2	4.35	-3.89	-2.09	1.45
NM_000963	PTGS2	prostaglandin-endoperoxide synthase 2	6.75	-3.72	4.66	-3.04
NM_001001890	RUNX1	runt-related transcription factor 1	-4.45	4.36	1.05	1.09
NM_005985	SNAI1	snail family zinc finger 1	6.44	-3.44	2.76	-2.59
NM_003068	SNAI2	snail family zinc finger 2	2.39	-2.15	1.59	-1.24

active PL: samples containing active CPD-photolyase

inactive PL: samples containing inactive CPD-photolyase

CPD-dependency of transcriptional changes of 9 genes selected on the basis of microarray data were confirmed by RT-qPCR

To validate the microarray data, we employed real time quantitative RT-PCR analyses. Regarding *ATF3*^[41], *CCNE1*^[45], *EGR1*^[41], *ID2*^[42], *PTGS2*^[44], *SNAI1*^[43] and *SNAI2*^[43], UV-induced upregulation of these genes has been previously described [41-45], and our results were in agreement with the literature. We found significant upregulation of the expression of *CDKN2B* (p15INK4b), and downregulation of the expression of *RUNX1* in response to UVB (Fig. 2). Furthermore, presence of active CPD-photolyase significantly prevented the changes in the expression of all tested genes (Fig. 2), thereby confirming the results of the microarray analysis.

Overexpression of cyclin E1 (*CCNE1*) and p15INK4b (*CDKN2B*) proteins in response to UVB is dependent on the generation of CPD and activation of JNK pathway

For further investigation, we selected two cell cycle-regulatory genes that were less characterized, related to their involvement in UVB-induced stress response. We have found that the expression of cyclin E1 and p15INK4b proteins were significantly increased at 24 h after UVB irradiation, but this increase was prevented by active CPD-photolyase (Fig. 3A-3B).

UVB can activate various protein kinases to regulate cell proliferation and survival pathways in human keratinocytes [46]. To investigate the signalling pathways involved in modulation of cyclin E1 and p15INK4b expression upon UVB exposure, HaCaT cells transfected with CPD-PL Ψ -mRNA were first exposed to specific inhibitors of JNK (SP600125), p38 MAPK (SB203580) or AKT (MK-2206) for 1 h, then immediately subjected to 20 mJ/cm² of UVB and subsequent photoreactivating light (active CPD-photolyase) or not (inactive CPD-photolyase). After photoreactivation, cells were cultured in keratinocyte medium containing inhibitor until harvested at 6 and 24 h. We determined the expression of cyclin E1 and p15INK4b proteins by western blot analysis. While suppression of p38 MAPK or AKT had no effect on UVB-induced increase in the levels of these proteins (data not shown), we found that the treatment of cells with the JNK inhibitor SP600125 abolished the induction of cyclin E1 and p15INK4b protein expression at 24 h after UVB (Fig. 4). Taken together, these results indicate that activation of JNK could be responsible for transducing the signal from CPD lesions towards the induction of *CCNE1* and *CDKN2B* gene expression in UVB-exposed human keratinocytes.

Discussion

The use of *in vitro*-transcribed messenger RNA for delivery of genetic material into mammalian cells has grown into a novel and alternative tool to oust DNA-based gene transfer in the last decade [47]. It is well documented that cells transfected with mRNA can synthesize the encoded protein [47]. We have previously shown that human cultured keratinocytes expressing CPD-photolyase from transfected *in vitro*-synthesized mRNA are suitable for investigating the cellular and molecular effects of UVB-induced CPDs [19]. Optimization of the transfection procedure resulted in 90% removal of CPDs within the first hour of photoreactivation, making this platform highly suitable for identification of CPD-dependent gene expression changes after UVB exposure. UV-induced mutagenesis is attributed to CPDs, which under normal conditions are repaired by the slow NER system [14]. Mutations in NER genes result in a less effective and error-prone DNA repair, which increases the probability of developing cancer [48]. Identification of the genes regulated by CPD photolesions might have clinical relevance, as it will facilitate defining novel targets for diagnosis or treatment of UVB-mediated skin diseases. We identified 1334 CPD-responsive genes, which represent more than 50% of the genes regulated by UVB at 6 and 24 h after the exposure, indicating that CPDs are major contributors to altered gene expression induced by UVB irradiation, as well as, to the harmful effects of UVC exposure [49]. These data also indicate that transcriptional change of a significant number of genes remained the same at 6 or 24 h after UVB exposure and subsequent photoreactivation in cells transfected with Ψ -mRNA encoding CPD-specific photolyase. This confirms that other UVB-related factors also play a role in gene regulation, but are independent from CPDs. Such factors include 6-4 photoproduct (6-4PP), which is the second most abundant UV-induced photolesion formed in DNA [50]. However, the removal of these photoproducts from the mammalian genome is very fast [14], thus 6-4PPs could potentially contribute to the early wave of UV-induced transcriptional

response [49]. In addition to 6-4PPs, other UVB-induced products, including reactive oxygen species, oxidized nucleobases (e.g. 8-oxo-7,8-dihydroxyguanine), crosslinked protein-DNA are likely to be responsible for CPD-independent transcriptional changes in human keratinocytes. A significant number of CPD-responsive genes (738 and 250 genes at 6 h and 24 h after the exposure, respectively) were downregulated, most likely due to the stalling of RNA polymerase II and inhibition of transcription elongation caused by UVB-induced DNA damage [51]. Furthermore, we found a markedly higher number of CPD-dependent genes to show altered expression levels at 6 h, as compared to 24 h.

Herein, we mainly focused on analysis of genes regulated by UVB-induced CPD lesions at 6 h after the exposure. Top functional categories were determined among these genes, and we found that CPD-related gene expression changes were mainly associated with regulation of the cell cycle and transcriptional machineries in response to UVB irradiation of human keratinocytes. Molecular studies have provided evidence that recognition of DNA damage, including UVB-induced photolesions, can temporarily halt cell cycle progression, allowing time for cells to repair damages prior to replication [52,53]. Unsuccessful repair of these photoproducts initiates intracellular apoptotic signalling in order to prevent the multiplication of mutated chromosomes, but may lead to a permanent cell cycle block, genomic instability or skin carcinogenesis [3,9,12,54]. The importance of cell cycle arrest is supported by studies in which the function of genes encoding cell cycle inhibitors (INK4 and Cip/Kip family) and cell cycle regulators (p53, Rb) were analysed [55-58]. A strong correlation has been demonstrated between the occurrence of CPD-caused “UV fingerprint” mutations in p53 gene and the development of skin cancer [59]. In addition, p53 was also shown to be regulated by UVB at a posttranslational rather than at the transcriptional level [60]. And that might be the reason, why we did not detect a change in the expression of p53 in cells exposed to UVB (GEO database - GSE65034), but observed CPD-dependent changes in mRNA levels of several p53

target genes, including MDM2, ATF3, CCNE1, SNAI1, CDK7, WWOX (Fig. 2, S1 and S2 Tables). These data demonstrated that germline mutations, chemical inactivation or alteration of cell cycle key regulators, including p53, result in perturbations of cell cycle checkpoint control leading to the transformation of the cells. Therefore, adequate regulation of cell cycle arrest is critical to eliminate mutated and potentially malignant cells. According to our microarray data, CPDs are the primary cause of UVB-induced cell cycle arrest. This finding is further supported by data demonstrating that photolyase-dependent removal of CPDs prevents UVB-induced upregulation of negative regulators of cell cycle, including *BTG2*, *CDKN2B* (p15), *CDKN1C* (p57), *GADD45B*, and *RGS2* (S3A Fig.). Our microarray experiment provides new data that CPDs are the primary cause of UVB-induced cell cycle arrest [52].

Among the regulated cell cycle-related genes, *CDKN2B*, which is involved in G1/S checkpoint control of cell cycle as well as gain and loss events for p15INK4b have been extensively studied in recent years [61,62] with less established roles in UVB-mediated cellular damage in keratinocyte biology. Results of our RT-qPCR and western blotting analyses showed that the CPD-photolyase mediated repair of UVB-induced CPDs prevented increased expression of *CDKN2B* (p15INK4b) mRNA and protein. Loss of p15INK4b function and *CDKN2B* mutations has been described in several types of tumors [57,61-63] confirming that the inactivation of p15INK4b significantly contributes to the transformation of normal cells into cancer cells. Mutations and deletions in p15INK4b have been demonstrated in melanoma tumorigenesis [64], and considered to be a heightened risk of melanoma according to several wide-range examinations [65,66]. Altered expression of *CDKN2B* (p15INK4b) mRNA level and new mutations have been detected in patients with actinic keratosis (AK) suggesting its possible role in AK development [67]. Taken together, our data strongly suggest the high relevance of CPDs in disruption of cell cycle progression.

In addition to cell cycle arrest, UVB exposure may affect the cell cycle machinery and cell proliferation via regulation of target genes involved in apoptosis or inflammation. The most studied gene associated with UVB-mediated cellular processes is cyclooxygenase 2 (*COX-2* or *PTGS2*). Its upregulation is described as a diagnostic marker and predictive factor in most tumors and other diseases related to chronic inflammation [68,69]. The role of *COX-2* inhibition is paramount important in prevention and treatment of different types of cancer [70]. *In vivo* studies have demonstrated that the use of specific inhibitors of *COX-2* leads to accumulation of cells in G0/G1 phase of cell cycle and reduced proliferation of cancer cells [69]. Our study confirmed upregulation of *COX-2* in UVB-irradiated keratinocytes, and here we also demonstrated that its increased expression was CPD-dependent (Fig. 2, S3E Fig.).

Furthermore, we have identified another gene, *CCNE1*, which similarly to *COX-2* related to enhanced cell proliferation and upregulated in a CPD-dependent manner. A study using a mouse model has shown that the cell cycle disturbance in epidermal keratinocytes subjected to an erythemalogenic dose of UVB irradiation is at least in part caused by increased expression of cyclins, including cyclin E1 [71]. Their data suggests that UVB-induced hyperplasia and tumorigenesis is partly mediated by the upregulation of cyclin E1 [71], it however has not been investigated in humans. Several studies suggested that *CCNE1* may represent a useful prognostic marker and has the potential to be a target for therapy in breast and ovarian cancer [72,73]. This has not yet been investigated in skin cancer.

The second best scored gene network was related to transcriptional machinery. We validated the microarray results for six transcriptional regulators, *ATF3*^[71], *EGRI*^[72], *ID2*^[73], *RUNX1*^[74], *SNAI1*^[75] and *SNAI2*^[75]. Mutations or altered expression of these genes has been reported in various types of cancer, including skin cancer [74-78]. Upregulation of *ATF3*^[41], *EGRI*^[41], *ID2*^[42], *SNAI1*^[43] and *SNAI2*^[43] has also been implicated in UV-induced cellular stress responses [41-43]. Here, we have demonstrated that expression of these transcription

regulators are CPD-dependent, which could serve as novel biomarkers for evaluation of the involvement of UVB in various photosensitive skin disorders or skin cancers. Our findings underscore that UVB-induced CPD photolesions play a critical role in tumor development, including skin carcinogenesis and not only by induction of mutations but also by changing the expression of physiologically important genes.

The question of how CPD photolesions activate intracellular signalling and how they modulate the expression of genes in cellular mechanisms (e.g. cell cycle arrest) in response to UVB irradiation has not been answered. Using CPD-photolyase expressing transgenic mice, it has been shown previously that unrepaired CPD photolesions are the major mediator of UV-induced transcriptional responses and induce S-phase cell cycle arrest [49]. UV radiation activates different signal transduction pathways in a wavelength and dose-dependent manner [79]. It is well established that these signal pathways are regulated by specific protein kinases including p38 kinase, PKC, AKT and JNK, which play a crucial role in the response network to skin damage caused by UV exposure [46]. We examined how specific inhibitors of protein kinases, such as p38 kinase, AKT and JNK, affect gene expression changes initiated by CPD photolesions. We found that only the JNK inhibitor influenced UVB-induced overexpression of cyclin E1 and p15INK4b proteins mainly at 24 hours after UVB irradiation. Reviewing the literature [80] and comparing the data to our microarray findings (S1 and S2 Tables) forty-two CPD-dependent genes could be identified that might be regulated through the activation of JNK. These findings indicate an important role for JNK kinases in the control of gene expression modulated by CPD photolesions. These genes are involved in cell adhesion, apoptosis, regulation of the cell cycle and transcriptional machineries, cytoskeletal remodelling, cellular development, growth and proliferation. Activation of *NF- κ B* and *AP-1* transcription factors (the major downstream targets of the JNK cascade to regulate the expression of several genes involved in proliferation and survival pathways or inflammation)

are candidates to mediate the effect of JNK upon UVB irradiation [46]. Increased levels of the activated form of JNK have been shown in UV exposed keratinocytes [81,82]. It has been reported that active JNK is mainly associated with keratinocyte proliferation and differentiation [80,83]. Some studies demonstrated enhanced JNK activity in psoriatic and wound-healing epidermal cells [84,85], as well as in cylindromas and other hair follicle derived tumors [86]. Moreover, experiments using animal or human tissue samples suggested that the JNK-Ap1 signalling pathway has an important role in development of squamous cell carcinoma and melanoma [86]. It is also possible that CPDs (or other UV-induced DNA-lesions) formed in the promoter or enhancer region of genes alter binding potentials of transcription factor leading to change in gene expression [87,88]. These published data raise the question whether expression of certain genes can be changed directly by UV-induced CPDs formed in their promoter region rather than through a damage-response signalling pathway. The answer to this question should come from studies with systematic investigation using specific inhibitors of signalling pathways to prove that indeed the observed transcriptional changes is mediated through a CPD-dependent signalling event or caused by a change in the promoter. Studies are ongoing to discern the mechanisms of CPD photolesion-mediated activation of JNK and its downstream effectors.

Conclusion

In vitro-transcribed mRNA can be easily generated and it is a new platform for the delivery of We demonstrated that *in vitro*-transcribed mRNA encoding non-human CPD-photolyase can efficiently be translated into a functional protein in cultured human keratinocytes. Using pseudouridine-modified mRNA encoding CPD-specific photolyase, which can specifically remove UVB-induced CPD lesions after exposure to photoreactivating light, we found that the CPD lesions represents the major contributors to the transcriptional response to UVB irradiation. Network analysis of CPD-regulated genes revealed that CPDs are principal

mediators of biological processes related to cell cycle signalling and transcriptional control. Consequently, the presence of CPDs modulated the transcription profile of many genes that are involved in the regulation of cell cycle (e.g. CCNE1, CDKN2B) or function as transcription factors (e.g. ATF3, ID2, RUNX1). Taken together, the results presented here demonstrates that an approach based on transfection of *in vitro*-transcribed mRNA is suitable for distinguishing UVB-induced CPD-dependent and -independent cellular mechanisms, and explore the molecular details of the involved signalling pathways.

therapeutic proteins opening wide perspectives for dermatological or other medical utilizations. This novel mRNA-based model provides an opportunity to identify additional UV-specific molecular targets and achieve a better understanding of UVB-mediated skin diseases.

References

1. Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of Nonmelanoma Skin Cancer in Relation to Ambient UV Radiation in White Populations, 1978-2012: Empirical Relationships. *JAMA Dermatol* 150: 1063-1071.
2. Matsumura Y, Ananthaswamy HN (2004) Toxic effects of ultraviolet radiation on the skin. *Toxicol Appl Pharmacol* 195: 298-308.
3. Brash DE, Wionkal NM, Remenyik E, van der Horst GT, Friedberg EC, et al. (2001) The DNA damage signal for Mdm2 regulation, Trp53 induction, and sunburn cell formation in vivo originates from actively transcribed genes. *J Invest Dermatol* 117: 1234-1240.
4. Freeman SE, Hacham H, Gange RW, Maytum DJ, Sutherland JC, et al. (1989) Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. *Proc Natl Acad Sci U S A* 86: 5605-5609.
5. Pfeifer GP (1997) Formation and processing of UV photoproducts: effects of DNA sequence and chromatin environment. *Photochem Photobiol* 65: 270-283.

- 482 6. Emri G, Wenczl E, Van Erp P, Jans J, Roza L, et al. (2000) Low doses of UVB or UVA induce
483 chromosomal aberrations in cultured human skin cells. *J Invest Dermatol* 115: 435-440.
- 484 7. You YH, Lee DH, Yoon JH, Nakajima S, Yasui A, et al. (2001) Cyclobutane pyrimidine dimers are
485 responsible for the vast majority of mutations induced by UVB irradiation in mammalian
486 cells. *J Biol Chem* 276: 44688-44694.
- 487 8. de Gruijl FR, Sterenborg HJ, Forbes PD, Davies RE, Cole C, et al. (1993) Wavelength dependence of
488 skin cancer induction by ultraviolet irradiation of albino hairless mice. *Cancer Res* 53: 53-60.
- 489 9. Jans J, Schul W, Sert YG, Rijksen Y, Rebel H, et al. (2005) Powerful skin cancer protection by a CPD-
490 photolyase transgene. *Curr Biol* 15: 105-115.
- 491 10. Jans J, Garinis GA, Schul W, van Oudenaren A, Moorhouse M, et al. (2006) Differential role of
492 basal keratinocytes in UV-induced immunosuppression and skin cancer. *Mol Cell Biol* 26:
493 8515-8526.
- 494 11. Kripke ML, Cox PA, Alas LG, Yarosh DB (1992) Pyrimidine dimers in DNA initiate systemic
495 immunosuppression in UV-irradiated mice. *Proc Natl Acad Sci U S A* 89: 7516-7520.
- 496 12. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, et al. (1996) Sunlight and sunburn in human
497 skin cancer: p53, apoptosis, and tumor promotion. *J Invest Dermatol Symp Proc* 1: 136-142.
- 498 13. Lehmann AR (1995) Nucleotide excision repair and the link with transcription. *Trends Biochem Sci*
499 20: 402-405.
- 500 14. Courdavault S, Baudouin C, Charveron M, Canguilhem B, Favier A, et al. (2005) Repair of the three
501 main types of bipyrimidine DNA photoproducts in human keratinocytes exposed to UVB and
502 UVA radiations. *DNA Repair (Amst)* 4: 836-844.
- 503 15. Sancar A (2008) Structure and function of photolyase and in vivo enzymology: 50th anniversary. *J*
504 *Biol Chem* 283: 32153-32157.
- 505 16. Li YF, Kim ST, Sancar A (1993) Evidence for lack of DNA photoreactivating enzyme in humans. *Proc*
506 *Natl Acad Sci U S A* 90: 4389-4393.

17. Berardesca E, Bertona M, Altabas K, Altabas V, Emanuele E (2012) Reduced ultraviolet-induced DNA damage and apoptosis in human skin with topical application of a photolyase-containing DNA repair enzyme cream: clues to skin cancer prevention. *Mol Med Rep* 5: 570-574.
18. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, et al. (2001) Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. *Xeroderma Pigmentosum Study Group. Lancet* 357: 926-929.
19. Boros G, Miko E, Muramatsu H, Weissman D, Emri E, et al. (2013) Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential. *J Photochem Photobiol B* 129: 93-99.
20. Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 23: 165-175.
21. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, et al. (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther* 16: 1833-1840.
22. Kariko K, Muramatsu H, Keller JM, Weissman D (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. *Mol Ther* 20: 948-953.
23. Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, et al. (2003) Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. *Nat Cell Biol* 5: 655-660.
24. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature* 406: 536-540.
25. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, et al. (2001) Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. *Hum Mol Genet* 10: 1793-1805.

- 533 26. Zhang ZK, Yang Y, Bai SR, Zhang GZ, Liu TH, et al. (2014) Screening for key genes associated with
534 atopic dermatitis with DNA microarrays. *Mol Med Rep* 9: 1049-1055.
- 535 27. Prasad NB, Fischer AC, Chuang AY, Wright JM, Yang T, et al. (2013) Differential expression of
536 degradome components in cutaneous squamous cell carcinomas. *Mod Pathol* 27: 945-957.
- 537 28. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, et al. (2009) Temporal changes in gene
538 expression in the skin of patients treated with isotretinoin provide insight into its mechanism
539 of action. *Dermatoendocrinol* 1: 177-187.
- 540 29. Sesto A, Navarro M, Burslem F, Jorcano JL (2002) Analysis of the ultraviolet B response in primary
541 human keratinocytes using oligonucleotide microarrays. *Proc Natl Acad Sci U S A* 99: 2965-
542 2970.
- 543 30. Gentile M, Latonen L, Laiho M (2003) Cell cycle arrest and apoptosis provoked by UV radiation-
544 induced DNA damage are transcriptionally highly divergent responses. *Nucleic Acids Res* 31:
545 4779-4790.
- 546 31. Valery C, Grob JJ, Verrando P (2001) Identification by cDNA microarray technology of genes
547 modulated by artificial ultraviolet radiation in normal human melanocytes: relation to
548 melanocarcinogenesis. *J Invest Dermatol* 117: 1471-1482.
- 549 32. Murakami T, Fujimoto M, Ohtsuki M, Nakagawa H (2001) Expression profiling of cancer-related
550 genes in human keratinocytes following non-lethal ultraviolet B irradiation. *J Dermatol Sci* 27:
551 121-129.
- 552 33. Takao J, Ariizumi K, Dougherty, II, Cruz PD, Jr. (2002) Genomic scale analysis of the human
553 keratinocyte response to broad-band ultraviolet-B irradiation. *Photodermatol Photoimmunol*
554 *Photomed* 18: 5-13.
- 555 34. Lee KM, Lee JG, Seo EY, Lee WH, Nam YH, et al. (2005) Analysis of genes responding to ultraviolet
556 B irradiation of HaCaT keratinocytes using a cDNA microarray. *Br J Dermatol* 152: 52-59.

- 557 35. da Costa RM, Riou L, Paquola A, Menck CF, Sarasin A (2005) Transcriptional profiles of
558 unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele
559 or the noncancer-prone XPB/TTD allele. *Oncogene* 24: 1359-1374.
- 560 36. Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy:
561 HPLC purification eliminates immune activation and improves translation of nucleoside-
562 modified, protein-encoding mRNA. *Nucleic Acids Res* 39: e142.
- 563 37. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal
564 keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J Cell*
565 *Biol* 106: 761-771.
- 566 38. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and
567 hybridization array data repository. *Nucleic Acids Res* 30: 207-210.
- 568 39. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time
569 quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods* 25: 402-408.
- 570 40. Balogh A, Paragh G, Jr., Juhasz A, Kobling T, Torocsik D, et al. (2008) Reference genes for
571 quantitative real time PCR in UVB irradiated keratinocytes. *J Photochem Photobiol B* 93: 133-
572 139.
- 573 41. Koch-Paiz CA, Amundson SA, Bittner ML, Meltzer PS, Fornace AJ, Jr. (2004) Functional genomics
574 of UV radiation responses in human cells. *Mutat Res* 549: 65-78.
- 575 42. Simbulan-Rosenthal CM, Trabosh V, Velarde A, Chou FP, Daher A, et al. (2005) Id2 protein is
576 selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and
577 inhibits differentiation. *Oncogene* 24: 5443-5458.
- 578 43. Hudson LG, Choi C, Newkirk KM, Parkhani J, Cooper KL, et al. (2007) Ultraviolet radiation
579 stimulates expression of Snail family transcription factors in keratinocytes. *Mol Carcinog* 46:
580 257-268.

- 581 44. Chen W, Tang Q, Gonzales MS, Bowden GT (2001) Role of p38 MAP kinases and ERK in mediating
 582 ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. *Oncogene*
 583 20: 3921-3926.
- 584 45. Stubbert LJ, Spronck JC, Hamill JD, McKay BC (2009) Ultraviolet light induces the sustained
 585 unscheduled expression of cyclin E in the absence of functional p53. *Cell Cycle* 8: 2995-3002.
- 586 46. Lopez-Camarillo C, Ocampo EA, Casamichana ML, Perez-Plasencia C, Alvarez-Sanchez E, et al.
 587 (2012) Protein kinases and transcription factors activation in response to UV-radiation of
 588 skin: implications for carcinogenesis. *Int J Mol Sci* 13: 142-172.
- 589 47. Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics - developing a new class of drugs.
 590 *Nat Rev Drug Discov* 13: 759-780.
- 591 48. Lehmann AR (2003) DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome
 592 and trichothiodystrophy. *Biochimie* 85: 1101-1111.
- 593 49. Garinis GA, Mitchell JR, Moorhouse MJ, Hanada K, de Waard H, et al. (2005) Transcriptome
 594 analysis reveals cyclobutane pyrimidine dimers as a major source of UV-induced DNA breaks.
 595 *EMBO J* 24: 3952-3962.
- 596 50. Mitchell DL (1988) The relative cytotoxicity of (6-4) photoproducts and cyclobutane dimers in
 597 mammalian cells. *Photochem Photobiol* 48: 51-57.
- 598 51. Tornaletti S (2005) Transcription arrest at DNA damage sites. *Mutat Res* 577: 131-145.
- 599 52. Lo HL, Nakajima S, Ma L, Walter B, Yasui A, et al. (2005) Differential biologic effects of CPD and 6-
 600 4PP UV-induced DNA damage on the induction of apoptosis and cell-cycle arrest. *BMC*
 601 *Cancer* 5: 135.
- 602 53. Cleaver JE, Laposa RR, Limoli CL (2003) DNA replication in the face of (In)surmountable odds. *Cell*
 603 *Cycle* 2: 310-315.
- 604 54. Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP (2010) Molecular mechanisms of ultraviolet
 605 radiation-induced DNA damage and repair. *J Nucleic Acids* 2010: 592980.

- 606 55. Stewart ZA, Westfall MD, Pietenpol JA (2003) Cell-cycle dysregulation and anticancer therapy.
607 Trends Pharmacol Sci 24: 139-145.
- 608 56. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase
609 progression. Genes Dev 13: 1501-1512.
- 610 57. Elsayed YA, Sausville EA (2001) Selected novel anticancer treatments targeting cell signaling
611 proteins. Oncologist 6: 517-537.
- 612 58. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, et al. (2011) Nucleoside
613 modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase
614 resistance to cleavage by RNase L. Nucleic Acids Res 39: 9329-9338.
- 615 59. Einspahr JG, Alberts DS, Warneke JA, Bozzo P, Basye J, et al. (1999) Relationship of p53 mutations
616 to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis.
617 Neoplasia 1: 468-475.
- 618 60. Goukassian DA, Eller MS, Yaar M, Gilchrest BA (1999) Thymidine dinucleotide mimics the effect of
619 solar simulated irradiation on p53 and p53-regulated proteins. J Invest Dermatol 112: 25-31.
- 620 61. Humeniuk R, Rosu-Myles M, Fares J, Koller R, Bies J, et al. (2013) The role of tumor suppressor
621 p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J 2: e99.
- 622 62. Humeniuk R, Koller R, Bies J, Aplan P, Wolff L (2014) Brief report: Loss of p15Ink4b accelerates
623 development of myeloid neoplasms in Nup98-HoxD13 transgenic mice. Stem Cells 32: 1361-
624 1366.
- 625 63. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk
626 inhibitors in human cancer. Adv Cancer Res 68: 67-108.
- 627 64. Soto Martinez JL, Cabrera Morales CM, Serrano Ortega S, Lopez-Nevot MA (2005) Mutation and
628 homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in
629 skin melanoma: p53, p21, p16 and p15. Clin Transl Oncol 7: 156-164.

- 630 65. Laud K, Marian C, Avril MF, Barrois M, Chompret A, et al. (2006) Comprehensive analysis of
631 CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to
632 be at heightened risk of melanoma. *J Med Genet* 43: 39-47.
- 633 66. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, et al. (2000) Analysis of G(1)/S checkpoint
634 regulators in metastatic melanoma. *Genes Chromosomes Cancer* 28: 404-414.
- 635 67. Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, et al. (2008) Genomic instability,
636 mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b),
637 p16(INK4a) and p53 in actinic keratosis. *Cancer Lett* 264: 145-161.
- 638 68. Jiao J, Mikulec C, Ishikawa TO, Magyar C, Dumlao DS, et al. (2014) Cell-type-specific roles for COX-
639 2 in UVB-induced skin cancer. *Carcinogenesis* 35: 1310-1319.
- 640 69. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in
641 cell proliferation and cell death in human malignancies. *Int J Cell Biol* 2010: 215158.
- 642 70. Vosooghi M, Amini M (2014) The discovery and development of cyclooxygenase-2 inhibitors as
643 potential anticancer therapies. *Expert Opin Drug Discov* 9: 255-267.
- 644 71. Berton TR, Pavone A, Fischer SM (2001) Ultraviolet-B irradiation alters the cell cycle machinery in
645 murine epidermis in vivo. *J Invest Dermatol* 117: 1171-1178.
- 646 72. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, et al. (2014) Cyclin E1 (CCNE1) as
647 independent positive prognostic factor in advanced stage serous ovarian cancer patients - a
648 study of the OVCAD consortium. *Eur J Cancer* 50: 99-110.
- 649 73. Hunt KK, Keyomarsi K (2005) Cyclin E as a prognostic and predictive marker in breast cancer.
650 *Semin Cancer Biol* 15: 319-326.
- 651 74. Xie JJ, Xie YM, Chen B, Pan F, Guo JC, et al. (2014) ATF3 functions as a novel tumor suppressor
652 with prognostic significance in esophageal squamous cell carcinoma. *Oncotarget* 5: 8569-
653 8582.

- 654 75. Kim YJ, Go H, Wu HG, Jeon YK, Park SW, et al. (2011) Immunohistochemical study identifying
655 prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy.
656 Head Neck 33: 1458-1466.
- 657 76. Ling F, Kang B, Sun XH (2014) Id proteins: small molecules, mighty regulators. Curr Top Dev Biol
658 110: 189-216.
- 659 77. Scheitz CJ, Tumbar T (2013) New insights into the role of Runx1 in epithelial stem cell biology and
660 pathology. J Cell Biochem 114: 985-993.
- 661 78. De Craene B, Denecker G, Vermassen P, Taminau J, Mauch C, et al. (2014) Epidermal Snail
662 expression drives skin cancer initiation and progression through enhanced cytoprotection,
663 epidermal stem/progenitor cell expansion and enhanced metastatic potential. Cell Death
664 Differ 21: 310-320.
- 665 79. Bender K, Blattner C, Knebel A, Iordanov M, Herrlich P, et al. (1997) UV-induced signal
666 transduction. J Photochem Photobiol B 37: 1-17.
- 667 80. Gazel A, Banno T, Walsh R, Blumenberg M (2006) Inhibition of JNK promotes differentiation of
668 epidermal keratinocytes. J Biol Chem 281: 20530-20541.
- 669 81. Assefa Z, Garmyn M, Bouillon R, Merlevede W, Vandenheede JR, et al. (1997) Differential
670 stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor
671 in human keratinocytes. J Invest Dermatol 108: 886-891.
- 672 82. Adachi M, Gazel A, Pintucci G, Shuck A, Shifteh S, et al. (2003) Specificity in stress response:
673 epidermal keratinocytes exhibit specialized UV-responsive signal transduction pathways.
674 DNA Cell Biol 22: 665-677.
- 675 83. Zhang JY, Green CL, Tao S, Khavari PA (2004) NF-kappaB RelA opposes epidermal proliferation
676 driven by TNFR1 and JNK. Genes Dev 18: 17-22.
- 677 84. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, et al. (2002) Extracellular
678 regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J
679 Dermatol Sci 30: 94-99.

85. Koehler K, Mielke K, Schunck M, Neumann C, Herdegen T, et al. (2011) Distinct roles of JNK-1 and ERK-2 isoforms in permeability barrier repair and wound healing. *Eur J Cell Biol* 90: 565-571.
86. Zhang JY, Selim MA (2012) The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer. *Am J Cancer Res* 2: 691-698.
87. Quan T, He T, Voorhees JJ, Fisher GJ (2005) Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. *J Biol Chem* 280: 8079-8085.
88. Holbrook NJ, Fornace AJ, Jr. (1991) Response to adversity: molecular control of gene activation following genotoxic stress. *New Biol* 3: 825-833.

Figure legends

Figure 1. Accelerated photorepair of CPDs in HaCaT cells transfected with CPD-PL Ψ -mRNA. HaCaT cells were transfected with lipofectamine-complexed Ψ -mRNA encoding CPD-photolyase. Twelve hours later, cells were subjected to 20 mJ/cm² UVB and immediately exposed to photoreactivating light (photoreactivated) or left in the dark (non-photoreactivated) for 1 h and then maintained at 37°C for 5 and 23 hs. After incubation at 5 and 23 h, genomic DNA was isolated at the indicated times after UVB irradiation and the amount of CPDs was measured by ELISA. The values were calculated relative to those obtained with cells that were not UVB-irradiated. Significance was assessed by unpaired, two-sample *t*-test, *p*<0.05. Error bars represent the standard error of the mean from three experiments performed independently.

Figure 2. Experimental verification of microarray results for 9 selected genes. HaCaT cells were exposed to 20 mJ/cm² UVB at 12 h after delivery of CPD-PL Ψ -mRNA. Immediately thereafter, cells were either subjected to photoreactivating light (active CPD-photolyase) or left in the dark (inactive CPD-photolyase) for 1 h. Following incubation total RNA was extracted at 5 and 23 h, then real-time RT-qPCR was performed to validate the CPD-dependent expression of ATF3, CCNE1, CDKN2B, EGR1, ID2, PTGS2, RUNX1,

SNAI1 and SNAI2. Values measured in UVB irradiated cells with or without photoreactivation were related to those measured in non-UVB irradiated cells that were transfected control Ψ -mRNA, (pecked lines). Asterisks indicate significant differences (two-tailed, unpaired *t*-test; $p < 0.05$) between photoreactivated (active CPD-photolyase) and non-photoreactivated (inactive CPD-photolyase) samples. The results of RT-qPCR are means \pm SEM from three independent experiments in triplicate.

Figure 3. Photorepair of CPDs prevents altered expression of cyclin E1 and p15INK4b protein in UVB irradiated HaCaT cells. Cells were transfected with lipofectamine-complexed CPD-PL Ψ -mRNA, 12 hs later irradiated with 20 mJ/cm² UVB and immediately exposed to photoreactivating light (active CPD-photolyase) or kept in the dark (inactive CPD-photolyase) for 1 h. Subsequently, cells were cultured at 37°C until harvested at the indicated time after UVB irradiation. (A) The expression of cyclin E1 and p15INK4b were analyzed by Western blot. (B) Quantitation of western blots displays relative changes in protein expression normalized to β -actin. Pixel densities were calculated relative to those obtained with cells that were not UVB irradiated (pecked lines). Significance was assessed by two-tailed, unpaired *t*-test (asterisk, $p < 0.05$) showing differences between photoreactivated and non-photoreactivated samples. Error bars represent the standard error of the mean. The results are means of three independent experiments.

Figure 4. Induction of cyclin E1 and p15INK4b protein expression upon UVB exposure is regulated through the JNK signalling pathway in HaCaT cells. Keratinocytes transfected with CPD-PL Ψ -mRNA were incubated in serum-free medium supplemented with JNK inhibitor (SP600125) for 1 h. Immediately thereafter, cells were irradiated with a physiological dose of UVB or left untreated followed by exposure to photoreactivating light (or not) for 1 h. The cells were cultured further in serum-free medium supplemented with the inhibitor. Cells were harvested for western blot assay at the indicated time. Protein levels of

cyclin E1, p15INK4b, and β -actin are noted. The figure shows representative results from three independent experiments.

Supporting information

S1 Table. List of all up and downregulated genes related to CPD lesions determined in CPD-PL Ψ -mRNA transfected human keratinocytes at 6 h after UVB exposure by microarray analyses.

S2 Table. List of all up and downregulated genes related to CPD lesions determined in CPD-PL Ψ -mRNA transfected human keratinocytes at 24 h after UVB exposure by microarray analyses.

S1 Fig. Divergence of UVB-mediated gene expression changes using CPD-specific photolyase encoded by *in vitro*-transcribed mRNA. To characterize the expression profile of CPD-related genes, oligonucleotide microarray was carried out as described in Materials and Methods. Bar graph represents the total number of UVB-responsive genes determined 6 and 24 h after the exposure. Bioset was divided into CPD-independent (the presence of active photolyase had no effect on the expression level of genes modified by UVB irradiation) and CPD-dependent (the presence of active photolyase has restored the expression level of genes modified by UVB irradiation) genes. Cut-off values for changes in gene expression were set at ± 2 -fold.

S2 Fig. Top network interactions among CPD-dependent genes determined at 6 and 24 h after UVB irradiation in CPD-PL Ψ -mRNA transfected keratinocytes. To analyze network interactions of CPD-dependent genes, datasets representing differentially regulated genes derived from microarray were imported into the Ingenuity Pathway Analysis (IPA) application. The list of the top three networks and associated cellular functions of all CPD-related gene datasets are shown with their respective scores and *p*-values ($p < 0.05$) obtained

from IPA (panel A). The score is derived from a p -value and indicates the likelihood of the focus genes in a network being found together due to random chance (defined as: $-\log_{10}(\text{p-value})$). The most highly rated networks of genes, determined 6 (panel B) and 24 h (panel C) after UVB irradiation, are illustrated with the significantly up- (red shaded) and downregulated (green shaded) genes modulated in a CPD-dependent manner. Genes in empty nodes were not identified as differentially expressed in our experiment and were generated automatically by IPA Knowledge Base indicating a relevance to this network. The genes marked with blue circle have been validated by RT-qPCR.

S3 Fig. Functional classification of CPD-related genes belonging to top rated networks determined by IPA. To analyze functional classification of CPD-responsive genes belonging to top networks, datasets derived from the results of network analysis were imported into the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool. The list of these CPD-dependent genes, determined at 6 and 24 h after UVB irradiation is shown according to their cellular functions (panel A-G). Gene expression values measured in photolyase mRNA transfected and UVB irradiated cells (PL+UVB) were compared to those measured in non-UVB irradiated control cells, while photolyase mRNA transfected, UVB-irradiated and photoreactivated samples (active CPD-photolyase) were compared to those that were photolyase mRNA transfected and UVB irradiated, but left without photoreactivation (inactive CPD-photolyase). Cut-off values for changes in gene expression were set at ± 2 -fold. To evaluate statistical analysis unpaired, Student's t -test followed by Benjamini-Hochberg corrections were used. The genes marked with red boxes were selected for further investigation. The blue box in (F) represents a gene (IL6) that was confirmed in previous work [19] to have CPD-dependent changes in expression.





Figure
[Click here to download Figure: Figure 2.tiff](#)







Figure
[Click here to download Figure: Figure 4.tiff](#)



[Click here to download Supporting Information: S1 Fig..pdf](#)

[Click here to download Supporting Information: S2 Fig..pdf](#)

[Click here to download Supporting Information: S3 Fig..pdf](#)

[Click here to download Supporting Information: S1 Table.docx](#)

[Click here to download Supporting Information: S2 Table.docx](#)

Identification of cyclobutane pyrimidine dimer-responsive genes using UVB-irradiated human keratinocytes transfected with *in vitro*-synthesized photolyase mRNA

Gábor Boros¹, Edit Miko^{1.#a}, Hiromi Muramatsu^{2.#b}, Drew Weissman³, Eszter Emri¹,
Gijsbertus T.J. van der Horst⁴, Andrea Szegedi^{1,5}, Irén Horkay¹, Gabriella Emri^{1.*}, Katalin
Karikó^{2.#b}, Éva Remenyik¹

¹Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen,
Hungary

²Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania,
United States of America

³Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United
States of America

⁴Department of Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.

⁵Department of Dermatological Allergology, Faculty of Medicine, University of Debrecen,
Debrecen, Hungary

*Corresponding author

E-mail: gemri@med.unideb.hu (GE)

^{#a} Current affiliation: MTA-DE Lendület Laboratory of Cellular Metabolism Research Group
of the Hungarian Academy of Sciences, Debrecen, Hungary

^{#b} Current affiliation: BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany

Abstract

Major biological effects of UVB are attributed to cyclobutane pyrimidine dimers (CPDs), the most common photolesions formed on DNA. To investigate the contribution of CPDs to UVB-induced changes of gene expression, a model system was established by transfecting keratinocytes with pseudouridine-modified mRNA (Ψ -mRNA) encoding CPD-photolyase. Microarray analyses of this model system demonstrated that more than 50% of the gene expression altered by UVB was mediated by CPD photolesions. Functional classification of the gene targets revealed strong effects of CPDs on the regulation of the cell cycle and transcriptional machineries. To confirm the microarray data, cell cycle-regulatory genes, *CCNE1* and *CDKN2B* that were induced exclusively by CPDs were selected for further investigation. Following UVB irradiation, expression of these genes increased significantly at both mRNA and protein levels, but not in cells transfected with CPD-photolyase Ψ -mRNA and exposed to photoreactivating light. Treatment of cells with inhibitors of c-Jun N-terminal kinase (JNK) ~~hindered~~ **blocked** the UVB-dependent upregulation of both genes suggesting a role for JNK in relaying the signal of UVB-induced CPDs into transcriptional responses. Thus, photolyase mRNA-based experimental platform demonstrates CPD-dependent and -independent events of UVB-induced cellular responses, and, as such, has the potential to identify novel molecular targets for treatment of UVB-mediated skin diseases.

Introduction

The incidence of keratinocyte-derived skin cancer, which is the most common human malignancy, continues to increase worldwide, thus presenting a serious challenge to healthcare systems [1]. Ultraviolet B (UVB) (290-320 nm) radiation is the main environmental risk factor for sunburn, skin carcinogenesis and premature skin ageing [2,3]. Cyclobutane pyrimidine dimers (CPDs) are the predominant photolesions caused by UVB radiation, and primarily they are responsible for these adverse effects [4]. CPDs are the most deleterious and premutagenic photolesions, due to their ability to distort the structure of the DNA, leading to disturbance of DNA replication and transcription [5,6]. The pathogenetic role of CPDs is further substantiated by presence of CPD-related signature mutations in genes involved in the formation of skin cancers [7], as well as, by the correlation between the action spectrum value for the induction of CPD photolesions and development of UV-induced skin cancer in animal models [8,9]. In addition, CPDs have been shown to mediate UVB-induced erythema [10] and immunosuppression [11,12]. Naturally, DNA lesions, including CPDs are excised by the nucleotide excision repair (NER) system of human keratinocytes [13]. However, the rate and accuracy of DNA repair by NER are suboptimal [14].

CPD-photolyase is a structure-specific DNA repair enzyme that specifically binds and cleaves CPDs using the energy of visible light ("photoreactivation"), thereby simply and rapidly restoring DNA integrity [15]. This enzyme functions in diverse organisms from bacteria to vertebrates but is absent in placental mammals, including humans, that must rely solely on the less potent NER to repair UV-induced DNA lesions [16]. Sunscreen lotions containing liposomal-encapsulated bacterial photolyase or CPD-specific endonuclease have been marketed for preventing UV-induced skin damages [17], especially in patients with NER-deficiency [18].

In a previous study, we applied a novel mRNA-based gene delivery method, and demonstrated that transfection of pseudouridine-modified mRNA (Ψ -mRNA) encoding *Potorous tridactylus* CPD-photolyase (CPD-PL) into human keratinocytes leads to rapid repair of DNA-damage [19]. Pseudouridine modifications increase mRNA stability [20], make it highly translatable [21,22] and abolish immunogenicity of the RNA [23]. It is well documented that CPD lesions are considered to be the principal mediator of UV-induced mutagenesis and DNA double-strand break (DSB) signalling [7,9]. However, so far, it has been unclear how CPDs change gene expression and cell activities. To gain insight, we performed a global analysis (microarray) of molecular networks. Most dermatological studies, in which microarray technology was used, analysed differential expression of genes comparing normal and pathologic skin samples in order to identify genes associated with a specific skin condition or with tumor progression [24-28]. Microarray platforms were also used to identify UV-regulated genes and have uncovered that significant change in the expression profiles of hundreds of genes are induced by UV. Altered expression of genes in response to UV irradiation have been determined in epidermal keratinocytes [29], fibroblasts [30] and melanocytes [31]. Microarray experiments have demonstrated that UVB exposure affects several biological processes indicating the complexity of UV-induced cellular activities. Studies performed on human keratinocytes identified UVB-induced genes that were involved in proteasome-mediated pathways, cytoskeleton organization, cell cycle and apoptosis networks, and control of basal transcription and translation leading to inhibition of cell growth [29,32-34]. Furthermore, it has been shown that the repair rate of DNA lesions alters the UV-induced transcription profile, thus suggesting that adequate removal of the photoproducts could avoid UV-related cutaneous pathologies [35]. However, until now, there was no suitable experimental platform to identify directly CPD-responsive genes in human cells, thus distinguish CPD-regulated cellular mechanisms from those mediated by other

UVB-induced derivatives, including diverse photoproducts, reactive oxygen species, cross-linked protein-DNA and other damaged macromolecules.

Here, we present data obtained by using human keratinocytes transfected with *in vitro*-synthesized nucleoside-modified mRNA encoding a marsupial-specific CPD-photolyase. This model system enabled us to distinguish between CPD-dependent and -independent cellular processes. We determined the UVB-induced transcriptional responses in human keratinocytes using the combination of a CPD-specific photolyase Ψ -mRNA delivery with a genomics approach. Pathway analysis revealed a strong effect of CPDs on the expression levels of genes involved in the control of the cell cycle and transcriptional machineries. Our findings demonstrate that the c-Jun N-terminal kinase (JNK) signalling pathway plays a role in conversion of the cues generated by UVB-induced CPDs into a transcriptional response.

Materials and Methods

RNA synthesis

Messenger RNAs were generated as previously described [19], using linearized plasmids (pTEV-CPD-PL-A101 and pTEVeGFP-A101) encoding codon-optimized *Potorous* CPD-photolyase (CPD-PL Ψ -mRNA) and enhanced green fluorescent protein (eGFP Ψ -mRNA). The CPD-photolyase gene from *Potorous tridactylus* (rat kangaroo) was synthesized by Entelechon (Bad Abbach, Germany). The Megascript T7 RNA polymerase kit (Ambion, Austin, TX) was used for transcription, and UTP was replaced with pseudouridine triphosphate (TriLink, San Diego, CA) [21]. To remove the template DNA Turbo DNase (Ambion) was added to the reaction mix. Pseudouridine-modified mRNAs were HPLC-purified as described [36] and provided with cap1 generated by using the m7G capping enzyme and 2'-O-methyltransferase according to the manufacturer (CellScript, Madison, WI).

The mRNAs were transcribed to contain 101 nt-long 3' poly(A) tail. Small aliquots of RNA samples were stored in siliconized tubes at -20°C .

Keratinocyte cell line

An established HaCaT cell line [37] was maintained in high glucose DMEM (Lonza, Verviers, Belgium) supplemented with 2 mM L-glutamine (Lonza), 10% fetal bovine serum (Lonza) and 0.5% antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA) at 37°C with 5% CO_2 .

Transient transfection and treatments

Transient transfection of Ψ -mRNA into HaCaT cells, UVB exposure and photoreactivation experiments were carried out, as previously described [19], except that a ratio of mRNA (0.25 μg) and Lipofectamine LTX-PLUS (Life Technologies) reagent (1.0 μl) in a final volume of 100 μl EpiLife keratinocyte growth medium (Life Technologies, Carlsbad, CA, USA) was used. Following a two-hour transfection, the lipofectamine-RNA complex was replaced with 100 μl fresh culture medium. At 12 h post transfection, the cell monolayer in a well of a 96-well plate, was covered with 50 μl Dulbecco's phosphate buffer saline (Life Technologies) and subjected to 20 mJ/cm^2 UVB using two TL-20W/12 ~~bulbs~~tubes (Philips). Proper dosage of UVB was determined by a UVX Digital Radiometer (UVP Inc., San Gabriel, CA, USA). Immediately after UVB treatment, cells were exposed to visible light ("photoreactivation") using F18W Daylight fluorescent ~~bulbs~~tubes (Sylvania) or kept in the dark for one hour. At 5 and 23 h following photoreactivation, total RNA and genomic DNA were isolated from the cells.

Enzyme-linked immunosorbent assay (ELISA)

Genomic DNA was extracted from HaCaT cell line using the Qiagen Blood and Cell Culture kit (Qiagen, Hilden, Germany), according to the manufacturer. A direct ELISA was applied

for detection of CPD, as previously described [19]. Anti-CPD monoclonal antibody (TDM-2, Cosmo Bio, Tokyo, Japan) diluted in PBS (1:1000) was used as primary antibody.

Microarray analysis

Total RNA was isolated from HaCaT cells using Trizol reagent (MRC, Cincinnati, OH, USA), according to the manufacturer's instructions. RNA samples were treated by DNase I (Fermentas, St. Leon-Rot, Germany) and their quality were analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Gene expression profiling of HaCaT cells transfected with CPD-photolyase mRNA was performed using a service provider (ChromoScience, Budapest, Hungary, <http://www.chromoscience.hu>). Briefly, cyanine 3-labeled cRNA was synthesized from 200 ng total RNA by the QuickAmp Labeling Kit (Agilent Technologies), according to the manufacturer. For each sample, 1650 ng of one-color labeled cRNA was hybridized to an Agilent 4x44 K Whole Human Genome Oligo (Agilent Technologies) microarray platform at 65°C for 17 h. All further steps were carried out according to the manufacturer (Agilent Technologies). The slides were scanned with the Agilent Microarray Scanner. Data were then normalized by the Feature Extraction software version 9.5 (Agilent Technologies) with default settings for one-color oligonucleotide microarrays and then transferred to GeneSpringGX program (Agilent Technologies) for further statistical evaluation. In GeneSpring, the normalization and data transformation steps recommended by Agilent Technologies for one-color data were applied at each time point. Microarray data have been submitted to Gene Expression Omnibus (GEO) [38] database and can be retrieved at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65034> (GEO Series accession number: GSE65034). Three replicates of the following 3 types of CPD-PL Ψ -mRNA transfected samples were studied by the microarray: non-irradiated, UVB-irradiated without photoreactivating light (inactive CPD-photolyase), UVB-irradiated plus photoreactivated (active CPD-photolyase). Genes showing statistically significant 2-fold

change were selected for further study by Ingenuity Pathway Analysis (IPA, Qiagen; <http://www.ingenuity.com/products/ipa>) and Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov>) gene functional classification tool.

Real-time quantitative RT-PCR analysis

To validate the microarray data, real-time quantitative reverse transcription (RT)-PCR was used. RT was performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), according to the manufacturer. RT reactions contained 500-500 ng of RNA. To quantitate the expression of candidate genes, the following TaqMan Gene Expression assays (Life Technologies) were used: *ATF3* (Hs00231069_m1), *CCNE1* (Hs01026536_m1), *CDKN2B* (p15INK4b) (Hs00793225_m1), *EGR1* (Hs00152928_m1), *ID2* (Hs04187239_m1), *PTGS2* (*COX-2*) (Hs00153133_m1), *RUNX1* (Hs00231079_m1), *SNAI2* (Hs00950344_m1), the sequences are proprietary and not released by the company. To determine mRNA expression of *SNAIL* the following custom-designed primers and probe set were used: Forward primer: 5'-ACT ATG CCG CGC TCT TTC-3'; Reverse primer: 5'-GCT GGA AGG TAA ACT CTG GAT-3'; and the probe sequence is: 5'-[6-carboxyfluorescein (FAM)] AAT CGG AAG CCT AAC TAC AGC GAG C [tetramethylrhodamine (TAMRA)]-3'. The composition of RT mixes, the PCR reactions and the RT-PCR protocols were carried out as previously described [19] using the ABI 7900 HT Sequence Detection System (Life Technologies). Relative RNA expression values were calculated using the $2^{-\Delta\Delta C_t}$ method [39] in which expression levels in samples containing active CPD-photolyase were compared to those containing inactive one. *SDHA* (Hs00188166_m1) and *PGK1* (Hs00943178_g1) mRNA levels that showed the smallest variation upon UVB exposure in keratinocytes [40] were used for normalization.

Western blot analysis

For Western blot analyses, whole cell extracts were prepared, as previously described [19]. Proteins (10 µg) were separated on 12% polyacrylamide gels and transferred to nitrocellulose membranes (BioRad, Berkeley, CA, USA). After blocking the membranes in 5% non-fat dry milk, the membranes were incubated with primary antibodies diluted (1:750) in 5% skimmed milk at 4°C overnight, then with the appropriate secondary antibodies (1:3000) at room temperature for 1 hour. The following primary antibodies were used: anti-CCNE1 (4129), anti-β-actin (3700) (Cell Signaling Technology, Danvers, MA, USA) and anti-CDKN2B (p15INK4b) (MA1-12294, Thermo Fisher Scientific, Rockford, IL, USA). Goat anti-mouse or anti-rabbit IgG conjugated with horseradish peroxidase (HRP) was used as a secondary antibody (BioRad). The visualization of proteins was achieved with ECL Prime Western blotting detection system (GE Healthcare, Little Chalfont, UK) and densitometry was performed using ImageJ public software (NIH, Bethesda, MD, USA).

Inhibitor treatment

Keratinocytes at 85% confluency were transfected with lipofectamine-complexed CPD-PL Ψ-mRNA. ~~cultured until reaching approximately 85-95% confluency and~~ Twelve hours later, cells were pretreated with specific inhibitors of JNK (SP600125), p38 MAPK (SB203580) or AKT (MK-2206-2HCl) ~~for 1 hour before UVB irradiation~~ at a final concentration of 40 µM, 10 µM and 10 µM, respectively for 1 hour before treatment with UVB and subsequent photoreactivation. All chemical agents were purchased from SelleckChem (Selleck Chemicals, Houston, TX, USA) and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Stock solutions were prepared according to the manufacturer and stored at -20°C.

Statistical evaluation

Identification of genes differentially expressed in microarray experiments was carried out by the unpaired, Student's *t*-test followed by Benjamini-Hochberg correction. Statistical analysis

of qRT-PCR data was performed using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). The significance of differences in terms of mRNA expression comparing UVB-irradiated samples to non-irradiated ones, or UVB-irradiated plus photoreactivated (active CPD-photolyase) samples to non-photoreactivated (inactive CPD-photolyase) samples, respectively, was determined by the two-tailed, unpaired *t*-test. A *p* value of equal to or less than 0.05 was considered statistically significant.

Results

Accelerated removal of CPD lesions in keratinocytes transfected with CPD-photolyase mRNA

To test the enzymatic activity of CPD-photolyase translated in HaCaT cells from the transfected mRNA (CPD-PL Ψ -mRNA), cells were subjected to a physiological dose of UVB (20 mJ/cm²) 12 h after transfection of lipofectamine-complexed CPD-PL Ψ -mRNA. Immediately thereafter, cells were either exposed to photoreactivating light, or left in the dark for 1 hour. Cells were harvested at 5 and 23 hours later, and CPD-specific ELISA was performed to measure the amount of CPDs formed in genomic DNA. The amount of CPDs in CPD-PL Ψ -mRNA transfected cells was reduced by 90% in those receiving photoreactivating light (photoreactivated), as compared to cells kept in the dark (non-photoreactivated) (Fig. 1). Cells transfected with control eGFP Ψ -mRNA contained the highest amount of CPD lesions at both 6 and 24 h after UVB irradiation (Fig. 1). A reduced amount of CPD lesions were measured in all irradiated samples at 24 h vs. at 6 h due to slower endogenous NER-mediated DNA repair.

Figure 1. Accelerated photorepair of CPDs in HaCaT cells transfected with CPD-PL Ψ -mRNA. HaCaT cells were transfected with lipofectamine-complexed Ψ -mRNA encoding CPD-photolyase. Twelve hours later, cells were subjected to 20 mJ/cm² UVB and

~~immediately exposed to photoreactivating light (photoreactivated) or left in the dark (non-photoreactivated) for 1 h and then maintained at 37°C for 5 and 23 h. After incubation 5 and 23 h, genomic DNA was isolated at the indicated times after UVB irradiation and the amount of CPDs was measured by ELISA. The values were calculated relative to those obtained with cells that were not UVB irradiated. Significance was assessed by unpaired, two-sample *t* test, $p < 0.05$. Error bars represent the standard error of the mean from three experiments performed independently.~~

CPD-dependent changes were distinguished within the UVB-induced alterations of gene expression in human keratinocytes

To determine the CPD-dependent gene expression profile of human keratinocytes exposed to UVB irradiation, an oligonucleotide-based DNA microarray analysis was performed in which HaCaT cells transfected with CPD-PL Ψ -mRNA were used. Total RNA was isolated at 6 and 24 h after UVB exposure and subsequent photoreactivation (or not). Gene expression values of UVB-irradiated plus photoreactivated samples (active CPD-photolyase) were compared to non-irradiated samples and to those that were UVB irradiated, but left without photoreactivation (inactive CPD-photolyase). UVB irradiated, but non-photoreactivated samples were also compared to non-irradiated samples. Cut-off values for changes in gene expression were set at ± 2 -fold, and according to this criterion, expression levels of 2,370 out of 41,000 genes were changed at 6 or 24 h after UVB exposure. Altered expression of 1,334 (56%) of UVB-regulated genes was restored in cells that contained active CPD-photolyase indicating that the changes in the expression of these genes were CPD-dependent (S1 Fig.). Importantly, more CPD-dependent gene expression changes (1,008 out of 1,334 genes) were observed at 6 h vs. 24 h, potentially due to the higher difference in CPD levels at 6 h comparing cells with active CPD-photolyase to those with inactive one (S1 Fig., S1 and S2

Tables). There are other reasons, such as transient expression of induced genes. On the other hand, CPD-dependent genes represented more than half of the UVB-regulated genes (1008 out of 1743 genes and 326 out of 627 genes at 6 and 24 h after UVB irradiation, respectively) at both time points after the exposure (S1 Fig., S1 and S2 Tables). These data suggest that UVB-induced CPDs mediate a significant portion of the transcriptional alterations after 6 and 24 hours in response to UVB irradiation of human keratinocytes.

UVB-induced, CPD-dependent genes are associated with cellular stress responses

To determine possible network interactions and associated biological functions of CPD-regulated genes, datasets representing all the differentially expressed genes derived from microarray analyses were imported into IPA and DAVID software. Using these applications, we determined that a majority of CPD-dependent genes at 6 h after UVB exposure belong to the regulatory network of *Cell Cycle and Gene Expression*, while those at the 24 h belong to the network of *Cellular Development, Growth and Proliferation* (S2A Fig., S3A-S3G Fig.). The top-rated network of CPD-regulated genes at 6 h after UVB irradiation was centered around a proto-oncogene (*c-Jun*); the prostaglandin-endoperoxide synthase 2 (*PTGS2*), which is a major mediator of inflammation, and the glucocorticoid receptor (*NR3C1*), which mainly functions as a transcription factor (S2B Fig.). In addition, c-Jun and interleukin 6 (*IL6*), the transcriptional regulator nuclear factor kappa B (*NF-κB*), *p38* and the protein kinase *ERK* were central nodes in the top network of CPD-dependent genes at 24 h after UVB exposure (S2C Fig.). 122 out of the 9661008 CPD-regulated genes belonged to the best-scored IPA network at 6 h after UVB and 60 out of the 475326 CPD-regulated genes at 24 h after the exposure (S2A Fig.). Functional classification of CPD-regulated genes within networks (S2B-S2C Fig.) suggested that a wide range of cell cycle-regulatory genes, positive or negative

281 regulators of the transcriptional and cell recovery machineries, proto-oncogenes, apoptosis
 282 and protein kinase related genes were uniquely induced or repressed by CPD photolesions
 283 (S3A-S3G Fig.). Nine genes regulated by CPDs were selected for further investigation based
 284 on the microarray data and their involvement in cell cycle regulation (*CCNE1*, *CDKN2B*),
 285 transcriptional regulation (*ATF3*, *EGR1*, *ID2*, *RUNX1*), epithelial to mesenchymal transition
 286 (*SNAI1*, *SNAI2*) and inflammation (*PTGS2*) (Table 1).

Table 1. Summarized fold change values by microarray results of the selected 9 CPD-dependent genes.

GenBank ID	Gene	Description	6 h after UVB irradiation		24 h after UVB irradiation	
			vs non-irradiated	active PL vs inactive PL	vs non-irradiated	active PL vs inactive PL
NM_001040619	ATF3	activating transcription factor 3	5.65	-3.30	1.85	-1.90
NM_001238	CCNE1	cyclin E1	2.87	-2.14	1.17	1.13
NM_004936	CDKN2B	cyclin-dependent kinase inhibitor 2B	7.76	-3.36	2.05	-2.06
NM_001964	EGR1	early growth response 1	2.51	-3.95	3.38	-2.39
NM_002166	ID2	inhibitor of DNA binding 2	4.35	-3.89	-2.09	1.45
NM_000963	PTGS2	prostaglandin-endoperoxide synthase 2	6.75	-3.72	4.66	-3.04
NM_001001890	RUNX1	runt-related transcription factor 1	-4.45	4.36	1.05	1.09
NM_005985	SNAI1	snail family zinc finger 1	6.44	-3.44	2.76	-2.59
NM_003068	SNAI2	snail family zinc finger 2	2.39	-2.15	1.59	-1.24

active PL: samples containing active CPD-photolyase

inactive PL: samples containing inactive CPD-photolyase

287 **CPD-dependency of transcriptional changes of 9 genes selected on** 288 **the basis of microarray data were confirmed by RT-qPCR**

289 To validate the microarray data, we employed real time quantitative RT-PCR analyses.
 290 Regarding *ATF3*^[41], *CCNE1*^[45], *EGR1*^[41], *ID2*^[42], *PTGS2*^[44], *SNAI1*^[43] and *SNAI2*^[43], UV-
 291 induced upregulation of these genes has been previously described [41-45], and our results

were in agreement with the literature. We found significant upregulation of the expression of *CDKN2B* (p15INK4b), and downregulation of the expression of *RUNX1* in response to UVB (Fig. 2). Furthermore, presence of active CPD-photolyase significantly prevented the changes in the expression of all tested genes (Fig. 2), thereby confirming the results of the microarray analysis.

Figure 2. Experimental verification of microarray results for 9 selected genes. HaCaT cells were exposed to 20 mJ/cm² UVB 12 h after delivery of CPD-PL Ψ mRNA. Immediately thereafter, cells were either subjected to photoreactivating light (active CPD-photolyase) or left in the dark (inactive CPD-photolyase) for 1 h. Following incubation total RNA was extracted at 5 and 23 h, then real time RT-qPCR was performed to validate the CPD-dependent expression of *ATF3*, *CCNE1*, *CDKN2B*, *EGR1*, *ID2*, *PTGS2*, *RUNX1*, *SNAI1* and *SNAI2*. Values measured in UVB irradiated cells with or without photoreactivation were related to those measured in non-UVB irradiated cells that were transfected control Ψ mRNA, (pecked lines). Asterisks indicate significant differences (two-tailed, unpaired *t* test; *p*<0.05) between photoreactivated (active CPD-photolyase) and non-photoreactivated (inactive CPD-photolyase) samples. The results of RT-qPCR are means \pm SEM from three independent experiments in triplicate.

Overexpression of cyclin E1 (*CCNE1*) and p15INK4b (*CDKN2B*) proteins in response to UVB is dependent on the generation of CPD and activation of JNK pathway

For further investigation, we selected two cell cycle-regulatory genes that were less characterized, related to their involvement in UVB-induced stress response. We have found that the expression of cyclin E1 and p15INK4b proteins were significantly increased at 24 h after UVB irradiation, but this increase was prevented by active CPD-photolyase (Fig. 3A-

3B).

Figure 3. Photorepair of CPDs prevents altered expression of cyclin E1 and p15INK4b protein in UVB irradiated HaCaT cells. Cells were transfected with lipofectamine-complexed CPD-PL Ψ -mRNA, 12 h later irradiated with 20 mJ/cm² UVB and immediately exposed to photoreactivating light (active CPD-photolyase) or kept in the dark (inactive CPD-photolyase) for 1 h. Subsequently, cells were cultured at 37°C until harvested at the indicated time after UVB irradiation. (A) The expression of cyclin E1 and p15INK4b were analyzed by Western blot. (B) Quantitation of western blots displays relative changes in protein expression normalized to β -actin. Pixel densities were calculated relative to those obtained with cells that were not UVB irradiated (pecked lines). Significance was assessed by two-tailed, unpaired *t*-test (asterisk, $p < 0.05$) showing differences between photoreactivated and non-photoreactivated samples. Error bars represent the standard error of the mean. The results are means of three independent experiments.

UVB can activate various protein kinases to regulate cell proliferation and survival pathways in human keratinocytes [46]. To investigate the signalling pathways involved in modulation of cyclin E1 and p15INK4b expression upon UVB exposure, HaCaT cells **transfected with CPD-PL Ψ -mRNA** were first exposed to specific inhibitors of JNK (SP600125), p38 MAPK (SB203580) or AKT (MK-2206-~~2HCl~~) for 1 h, then immediately subjected to 20 mJ/cm² of UVB **and subsequent photoreactivating light (active CPD-photolyase) or not (inactive CPD-photolyase).** **After photoreactivation,** ~~Subsequently,~~ cells were cultured in keratinocyte medium containing inhibitor until harvested at 6 and 24 h. We determined the expression of cyclin E1 and p15INK4b proteins by western blot analysis. While suppression of p38 MAPK or AKT had no effect on UVB-induced increase in the levels of these proteins (data not shown), we found that the treatment of cells with the JNK inhibitor SP600125 abolished the induction of cyclin E1 and p15INK4b protein expression at 24 h after UVB (Fig. 4). Taken

together, these results indicate that activation of JNK could be responsible for transducing the signal from CPD lesions towards the induction of *CCNE1* and *CDKN2B* gene expression in UVB-exposed human keratinocytes.

~~**Figure 4. Induction of cyclin E1 and p15INK4b protein expression upon UVB exposure is regulated through the JNK signalling pathway in HaCaT cells.** Keratinocytes were incubated in serum free medium supplemented with JNK inhibitor (SP600125) for 1 h, then irradiated with a physiological dose of UVB or left untreated. The cells were cultured further in serum free medium supplemented with the inhibitor. Cells were harvested for western blot assay at the indicated time. Protein levels of cyclin E1, p15INK4b, and β -actin are noted. The figure shows representative results from three independent experiments.~~

Discussion

The use of *in vitro*-transcribed messenger RNA for delivery of genetic material into mammalian cells has grown into a novel and alternative tool to oust DNA-based gene transfer in the last decade [47]. It is well documented that cells transfected with mRNA can synthesize the encoded protein [47]. We have previously shown that human cultured keratinocytes expressing CPD-photolyase from transfected *in vitro*-synthesized mRNA are suitable for investigating the cellular and molecular effects of UVB-induced CPDs [19]. Optimization of the transfection procedure resulted in 90% removal of CPDs within the first hour of photoreactivation, making this platform highly suitable for identification of CPD-dependent gene expression changes after UVB exposure. UV-induced mutagenesis is attributed to CPDs, which under normal conditions are repaired by the slow NER system [14]. Mutations in NER genes result in a less effective and error-prone DNA repair, which increases the probability of developing cancer [48]. Identification of the genes regulated by CPD photolesions might have clinical relevance, as it will facilitate defining novel targets for diagnosis or treatment of UVB-mediated skin diseases. We identified 1334 CPD-responsive genes, which represent

more than 50% of the genes regulated by UVB at 6 and 24 h after the exposure, indicating that CPDs are major contributors to altered gene expression induced by UVB irradiation, as well as, to the harmful effects of UVC exposure [49]. These data also indicate that transcriptional change of a significant number of genes remained the same at 6 or 24 h after UVB exposure and subsequent photoreactivation in cells transfected with Ψ -mRNA encoding CPD-specific photolyase. This confirms that other UVB-related factors also play a role in gene regulation, but are independent from CPDs. Such factors include 6-4 photoproduct (6-4PP), which is the second most abundant UV-induced photolesion formed in DNA [50]. However, the removal of these photoproducts from the mammalian genome is very fast [14], thus 6-4PPs could potentially contribute to the early wave of UV-induced transcriptional response [49]. In addition to 6-4PPs, other UVB-induced products, including reactive oxygen species, oxidized nucleobases (e.g. 8-oxo-7,8-dihydroxyguanine), crosslinked protein-DNA are likely to be responsible for CPD-independent transcriptional changes in human keratinocytes. A significant number of ~~these~~ CPD-responsive genes (738 and 250 genes at 6 h and 24 h after the exposure, respectively) were downregulated, most likely due to the stalling of RNA polymerase II and inhibition of transcription elongation caused by UVB-induced DNA damage [51]. Furthermore, we found a markedly higher number of CPD-dependent genes to show altered expression levels at 6 h, as compared to 24 h.

Herein, we mainly focused on analysis of genes regulated by UVB-induced CPD lesions at 6 h after the exposure. Top functional categories were determined among these genes, and we found that CPD-related gene expression changes were mainly associated with regulation of the cell cycle and transcriptional machineries in response to UVB irradiation of human keratinocytes. Molecular studies have provided evidence that recognition of DNA damage, including UVB-induced photolesions, can temporarily halt cell cycle progression, allowing time for cells to repair damages prior to replication [52,53]. Unsuccessful repair of these

photoproducts initiates intracellular apoptotic signalling in order to prevent the multiplication of mutated chromosomes, but may lead to a permanent cell cycle block, genomic instability or skin carcinogenesis [3,9,12,54]. The importance of cell cycle arrest is supported by studies in which the function of genes encoding cell cycle inhibitors (INK4 and Cip/Kip family) and cell cycle regulators (p53, Rb) were analysed [55-58]. A strong correlation has been demonstrated between the occurrence of CPD-caused “UV fingerprint” mutations in p53 gene and the development of skin cancer [59]. In addition, p53 was also shown to be regulated by UVB at a posttranslational rather than at the transcriptional level [60]. And that might be the reason, why we did not detect a change in the expression of p53 in cells exposed to UVB (GEO database - GSE65034), but observed CPD-dependent changes in mRNA levels of several p53 target genes, including MDM2, ATF3, CCNE1, SNAIL, CDK7, WWOX (Fig. 2, S1 and S2 Tables). These data demonstrated that germline mutations ~~or~~ chemical inactivation ~~or~~ alteration of ~~these~~ cell cycle key regulators, including p53, ~~could~~ result in perturbations of cell cycle checkpoint control leading to the transformation of the cells. Therefore, adequate regulation of cell cycle arrest is critical to eliminate mutated and potentially malignant cells. According to our microarray data, CPDs are the primary cause of UVB-induced cell cycle arrest. This finding is further supported by data demonstrating that photolyase-dependent removal of CPDs prevents UVB-induced upregulation of negative regulators of cell cycle, including *BTG2*, *CDKN2B* (p15), *CDKN1C* (p57), *GADD45B*, and *RGS2* (S3A Fig.). Our microarray experiment provides new data that CPDs are the primary cause of UVB-induced cell cycle arrest [52].

Among the regulated cell cycle-related genes, *CDKN2B*, which is involved in G1/S checkpoint control of cell cycle as well as gain and loss events for p15INK4b have been extensively studied in recent years [61,62] with less established roles in UVB-mediated cellular damage in keratinocyte biology. Results of our RT-qPCR and western blotting

analyses showed that the CPD-photolyase mediated repair of UVB-induced CPDs prevented increased expression of *CDKN2B* (p15INK4b) mRNA and protein. Loss of p15INK4b function and *CDKN2B* mutations has been described in several types of tumors [57,61-63] confirming that the inactivation of p15INK4b significantly contributes to the transformation of normal cells into cancer cells. Mutations and deletions in p15INK4b have been demonstrated in melanoma tumorigenesis [64], and considered to be a heightened risk of melanoma according to several wide-range examinations [65,66]. Altered expression of *CDKN2B* (p15INK4b) mRNA level and new mutations have been detected in patients with actinic keratosis (AK) suggesting its possible role in AK development [67]. Taken together, our data strongly suggest the high relevance of CPDs in disruption of cell cycle progression.

In addition to cell cycle arrest, UVB exposure may affect the cell cycle machinery and cell proliferation via regulation of target genes involved in apoptosis or inflammation. The most studied gene associated with UVB-mediated cellular processes is cyclooxygenase 2 (*COX-2* or *PTGS2*). Its upregulation is described as a diagnostic marker and predictive factor in most tumors and other diseases related to chronic inflammation [68,69]. The role of *COX-2* inhibition is paramount important in prevention and treatment of different types of cancer [70]. *In vivo* studies have demonstrated that the use of specific inhibitors of *COX-2* leads to accumulation of cells in G0/G1 phase of cell cycle and reduced proliferation of cancer cells [69]. Our study confirmed upregulation of *COX-2* in UVB-irradiated keratinocytes, and here we also demonstrated that its increased expression was CPD-dependent (Fig. 2, S3E Fig.).

Furthermore, we have identified another gene, *CCNE1*, which similarly to *COX-2* related to enhanced cell proliferation and upregulated in a CPD-dependent manner. A study using a mouse model has shown that the cell cycle disturbance in epidermal keratinocytes subjected to an erythemal dose of UVB irradiation is at least in part caused by increased expression of cyclins, including cyclin E1 [71]. Their data suggests that UVB-induced

hyperplasia and tumorigenesis is partly mediated by the upregulation of cyclin E1 [71], it however has not been investigated in humans. Several studies suggested that *CCNE1* may represent a useful prognostic marker and has the potential to be a target for therapy in breast and ovarian cancer [72,73]. This has not yet been investigated in skin cancer.

The second best scored gene network was related to transcriptional machinery. We validated the microarray results for six transcriptional regulators, *ATF3*^[71], *EGRI*^[72], *ID2*^[73], *RUNX1*^[74], *SNAI1*^[75] and *SNAI2*^[75]. Mutations or altered expression of these genes has been reported in various types of cancer, including skin cancer [74-78]. Upregulation of *ATF3*^[41], *EGRI*^[41], *ID2*^[42], *SNAI1*^[43] and *SNAI2*^[43] has also been implicated in UV-induced cellular stress responses [41-43]. Here, we have demonstrated that expression of these transcription regulators are CPD-dependent, which could serve as novel biomarkers for evaluation of the involvement of UVB in various photosensitive skin disorders or skin cancers. Our findings underscore that UVB-induced CPD photolesions play a critical role in tumor development, including skin carcinogenesis and not only by induction of mutations but also by changing the expression of physiologically important genes.

The question of how CPD photolesions activate intracellular signalling and how they modulate the expression of genes in cellular mechanisms (e.g. cell cycle arrest) in response to UVB irradiation has not been answered. Using CPD-photolyase expressing transgenic mice, it has been shown previously that unrepaired CPD photolesions are the major mediator of UV-induced transcriptional responses and induce S-phase cell cycle arrest [49]. UV radiation activates different signal transduction pathways in a wavelength and dose-dependent manner [79]. It is well established that these signal pathways are regulated by specific protein kinases including p38 kinase, PKC, AKT and JNK, which play a crucial role in the response network to skin damage caused by UV exposure [46]. We examined how specific inhibitors of protein kinases, such as p38 kinase, AKT and JNK, affect gene expression changes initiated by CPD

photolesions. We found that only the JNK inhibitor influenced UVB-induced overexpression of cyclin E1 and p15INK4b proteins mainly at 24 hours after UVB irradiation. Reviewing the literature [80] and comparing the data to our microarray findings (S1 and S2 Tables) forty-two CPD-dependent genes could be identified that might be regulated through the activation of JNK. These findings indicate an important role for JNK kinases in the control of gene expression modulated by CPD photolesions. These genes are involved in cell adhesion, apoptosis, regulation of the cell cycle and transcriptional machineries, cytoskeletal remodelling, cellular development, growth and proliferation. Activation of *NF-κB* and *AP-1* transcription factors (the major downstream targets of the JNK cascade to regulate the expression of several genes involved in proliferation and survival pathways or inflammation) are candidates to mediate the effect of JNK upon UVB irradiation [46]. Increased levels of the activated form of JNK have been shown in UV exposed keratinocytes [81,82]. It has been reported that active JNK is mainly associated with keratinocyte proliferation and differentiation [80,83]. Some studies demonstrated enhanced JNK activity in psoriatic and wound-healing epidermal cells [84,85], as well as in cylindromas and other hair follicle derived tumors [86]. Moreover, experiments using animal or human tissue samples suggested that the JNK-Ap1 signalling pathway has an important role in development of squamous cell carcinoma and melanoma [86]. It is also possible that CPDs (or other UV-induced DNA-lesions) formed in the promoter or enhancer region of genes alter binding potentials of transcription factor leading to change in gene expression [87,88]. These published data raise the question whether expression of certain genes can be changed directly by UV-induced CPDs formed in their promoter region rather than through a damage-response signalling pathway. The answer to this question should come from studies with systematic investigation using specific inhibitors of signalling pathways to prove that indeed the observed transcriptional changes is mediated through a CPD-dependent signalling event or caused by a

change in the promoter. Studies are ongoing to discern the mechanisms of CPD photolesion-mediated activation of JNK and its downstream effectors.

Conclusion

In vitro-transcribed mRNA can be easily generated and it is a new platform for the delivery of
We demonstrated that *in vitro*-transcribed mRNA encoding non-human CPD-photolyase can
efficiently be translated into a functional protein in cultured human keratinocytes. Using
pseudouridine-modified mRNA encoding CPD-specific photolyase, which can specifically
remove UVB-induced CPD lesions after exposure to photoreactivating light, we found that
the CPD lesions represents the major contributors to the transcriptional response to UVB
irradiation. Network analysis of CPD-regulated genes revealed that CPDs are principal
mediators of biological processes related to cell cycle signalling and transcriptional control.
Consequently, the presence of CPDs modulated the transcription profile of many genes that
are involved in the regulation of cell cycle (e.g. CCNE1, CDKN2B) or function as
transcription factors (e.g. ATF3, ID2, RUNX1). Taken together, the results presented here
demonstrates that an approach based on transfection of *in vitro*-transcribed mRNA is suitable
for distinguishing UVB-induced CPD-dependent and -independent cellular mechanisms, and
explore the molecular details of the involved signalling pathways.
therapeutic proteins opening wide perspectives for dermatological or other medical
utilizations. This novel mRNA-based model provides an opportunity to identify additional
UV-specific molecular targets and achieve a better understanding of UVB-mediated skin
diseases.

~~We demonstrated that nucleoside-modified mRNA encoding non-human CPD-photolyase~~
~~can efficiently be translated into a functional protein in cultured human keratinocytes. *In*~~
~~*vitro*-transcribed mRNA is commercially available and is a new platform for the delivery of~~
~~therapeutic proteins opening wide perspectives for dermatological or other medical~~

~~utilizations. We also demonstrated that our mRNA-based model is suitable for investigating CPD-dependent cellular functions and provides an opportunity to identify novel UV-specific molecular targets and achieve a better understanding of UVB-mediated skin diseases.~~

References

1. Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of Nonmelanoma Skin Cancer in Relation to Ambient UV Radiation in White Populations, 1978-2012: Empirical Relationships. JAMA Dermatol 150: 1063-1071.
2. Matsumura Y, Ananthaswamy HN (2004) Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 195: 298-308.
3. Brash DE, Wikonkal NM, Remenyik E, van der Horst GT, Friedberg EC, et al. (2001) The DNA damage signal for Mdm2 regulation, Trp53 induction, and sunburn cell formation in vivo originates from actively transcribed genes. J Invest Dermatol 117: 1234-1240.
4. Freeman SE, Hacham H, Gange RW, Maytum DJ, Sutherland JC, et al. (1989) Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. Proc Natl Acad Sci U S A 86: 5605-5609.
5. Pfeifer GP (1997) Formation and processing of UV photoproducts: effects of DNA sequence and chromatin environment. Photochem Photobiol 65: 270-283.
6. Emri G, Wenczl E, Van Erp P, Jans J, Roza L, et al. (2000) Low doses of UVB or UVA induce chromosomal aberrations in cultured human skin cells. J Invest Dermatol 115: 435-440.
7. You YH, Lee DH, Yoon JH, Nakajima S, Yasui A, et al. (2001) Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells. J Biol Chem 276: 44688-44694.
8. de Gruijl FR, Sterenborg HJ, Forbes PD, Davies RE, Cole C, et al. (1993) Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res 53: 53-60.

- 540 9. Jans J, Schul W, Sert YG, Rijksen Y, Rebel H, et al. (2005) Powerful skin cancer protection by a CPD-
541 photolyase transgene. *Curr Biol* 15: 105-115.
- 542 10. Jans J, Garinis GA, Schul W, van Oudenaren A, Moorhouse M, et al. (2006) Differential role of
543 basal keratinocytes in UV-induced immunosuppression and skin cancer. *Mol Cell Biol* 26:
544 8515-8526.
- 545 11. Kripke ML, Cox PA, Alas LG, Yarosh DB (1992) Pyrimidine dimers in DNA initiate systemic
546 immunosuppression in UV-irradiated mice. *Proc Natl Acad Sci U S A* 89: 7516-7520.
- 547 12. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, et al. (1996) Sunlight and sunburn in human
548 skin cancer: p53, apoptosis, and tumor promotion. *J Investig Dermatol Symp Proc* 1: 136-142.
- 549 13. Lehmann AR (1995) Nucleotide excision repair and the link with transcription. *Trends Biochem Sci*
550 20: 402-405.
- 551 14. Courdavault S, Baudouin C, Charveron M, Canguilhem B, Favier A, et al. (2005) Repair of the three
552 main types of bipyrimidine DNA photoproducts in human keratinocytes exposed to UVB and
553 UVA radiations. *DNA Repair (Amst)* 4: 836-844.
- 554 15. Sancar A (2008) Structure and function of photolyase and in vivo enzymology: 50th anniversary. *J*
555 *Biol Chem* 283: 32153-32157.
- 556 16. Li YF, Kim ST, Sancar A (1993) Evidence for lack of DNA photoreactivating enzyme in humans. *Proc*
557 *Natl Acad Sci U S A* 90: 4389-4393.
- 558 17. Berardesca E, Bertona M, Altabas K, Altabas V, Emanuele E (2012) Reduced ultraviolet-induced
559 DNA damage and apoptosis in human skin with topical application of a photolyase-containing
560 DNA repair enzyme cream: clues to skin cancer prevention. *Mol Med Rep* 5: 570-574.
- 561 18. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, et al. (2001) Effect of topically applied T4
562 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised
563 study. *Xeroderma Pigmentosum Study Group. Lancet* 357: 926-929.
- 564 19. Boros G, Miko E, Muramatsu H, Weissman D, Emri E, et al. (2013) Transfection of pseudouridine-
565 modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human

- 566 keratinocytes: a new approach with future therapeutic potential. *J Photochem Photobiol B*
 567 129: 93-99.
- 568 20. Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like
 569 receptors: the impact of nucleoside modification and the evolutionary origin of RNA.
 570 *Immunity* 23: 165-175.
- 571 21. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, et al. (2008) Incorporation of pseudouridine
 572 into mRNA yields superior nonimmunogenic vector with increased translational capacity and
 573 biological stability. *Mol Ther* 16: 1833-1840.
- 574 22. Kariko K, Muramatsu H, Keller JM, Weissman D (2012) Increased erythropoiesis in mice injected
 575 with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.
 576 *Mol Ther* 20: 948-953.
- 577 23. Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, et al. (2003) Inactivating E2f1 reverts
 578 apoptosis resistance and cancer sensitivity in Trp53-deficient mice. *Nat Cell Biol* 5: 655-660.
- 579 24. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous
 580 malignant melanoma by gene expression profiling. *Nature* 406: 536-540.
- 581 25. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, et al. (2001) Insights into psoriasis and other
 582 inflammatory diseases from large-scale gene expression studies. *Hum Mol Genet* 10: 1793-
 583 1805.
- 584 26. Zhang ZK, Yang Y, Bai SR, Zhang GZ, Liu TH, et al. (2014) Screening for key genes associated with
 585 atopic dermatitis with DNA microarrays. *Mol Med Rep* 9: 1049-1055.
- 586 27. Prasad NB, Fischer AC, Chuang AY, Wright JM, Yang T, et al. (2013) Differential expression of
 587 degradome components in cutaneous squamous cell carcinomas. *Mod Pathol* 27: 945-957.
- 588 28. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, et al. (2009) Temporal changes in gene
 589 expression in the skin of patients treated with isotretinoin provide insight into its mechanism
 590 of action. *Dermatoendocrinol* 1: 177-187.

- 591 29. Sesto A, Navarro M, Burslem F, Jorcano JL (2002) Analysis of the ultraviolet B response in primary
 592 human keratinocytes using oligonucleotide microarrays. *Proc Natl Acad Sci U S A* 99: 2965-
 593 2970.
- 594 30. Gentile M, Latonen L, Laiho M (2003) Cell cycle arrest and apoptosis provoked by UV radiation-
 595 induced DNA damage are transcriptionally highly divergent responses. *Nucleic Acids Res* 31:
 596 4779-4790.
- 597 31. Valery C, Grob JJ, Verrando P (2001) Identification by cDNA microarray technology of genes
 598 modulated by artificial ultraviolet radiation in normal human melanocytes: relation to
 599 melanocarcinogenesis. *J Invest Dermatol* 117: 1471-1482.
- 600 32. Murakami T, Fujimoto M, Ohtsuki M, Nakagawa H (2001) Expression profiling of cancer-related
 601 genes in human keratinocytes following non-lethal ultraviolet B irradiation. *J Dermatol Sci* 27:
 602 121-129.
- 603 33. Takao J, Ariizumi K, Dougherty, II, Cruz PD, Jr. (2002) Genomic scale analysis of the human
 604 keratinocyte response to broad-band ultraviolet-B irradiation. *Photodermatol Photoimmunol*
 605 *Photomed* 18: 5-13.
- 606 34. Lee KM, Lee JG, Seo EY, Lee WH, Nam YH, et al. (2005) Analysis of genes responding to ultraviolet
 607 B irradiation of HaCaT keratinocytes using a cDNA microarray. *Br J Dermatol* 152: 52-59.
- 608 35. da Costa RM, Riou L, Paquola A, Menck CF, Sarasin A (2005) Transcriptional profiles of
 609 unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele
 610 or the noncancer-prone XPB/TTD allele. *Oncogene* 24: 1359-1374.
- 611 36. Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy:
 612 HPLC purification eliminates immune activation and improves translation of nucleoside-
 613 modified, protein-encoding mRNA. *Nucleic Acids Res* 39: e142.
- 614 37. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal
 615 keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J Cell*
 616 *Biol* 106: 761-771.

- 617 38. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and
618 hybridization array data repository. *Nucleic Acids Res* 30: 207-210.
- 619 39. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time
620 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408.
- 621 40. Balogh A, Paragh G, Jr., Juhasz A, Kobling T, Torocsik D, et al. (2008) Reference genes for
622 quantitative real time PCR in UVB irradiated keratinocytes. *J Photochem Photobiol B* 93: 133-
623 139.
- 624 41. Koch-Paiz CA, Amundson SA, Bittner ML, Meltzer PS, Fornace AJ, Jr. (2004) Functional genomics
625 of UV radiation responses in human cells. *Mutat Res* 549: 65-78.
- 626 42. Simbulan-Rosenthal CM, Trabosh V, Velarde A, Chou FP, Daher A, et al. (2005) Id2 protein is
627 selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and
628 inhibits differentiation. *Oncogene* 24: 5443-5458.
- 629 43. Hudson LG, Choi C, Newkirk KM, Parkhani J, Cooper KL, et al. (2007) Ultraviolet radiation
630 stimulates expression of Snail family transcription factors in keratinocytes. *Mol Carcinog* 46:
631 257-268.
- 632 44. Chen W, Tang Q, Gonzales MS, Bowden GT (2001) Role of p38 MAP kinases and ERK in mediating
633 ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. *Oncogene*
634 20: 3921-3926.
- 635 45. Stubbert LJ, Spronck JC, Hamill JD, McKay BC (2009) Ultraviolet light induces the sustained
636 unscheduled expression of cyclin E in the absence of functional p53. *Cell Cycle* 8: 2995-3002.
- 637 46. Lopez-Camarillo C, Ocampo EA, Casamichana ML, Perez-Plasencia C, Alvarez-Sanchez E, et al.
638 (2012) Protein kinases and transcription factors activation in response to UV-radiation of
639 skin: implications for carcinogenesis. *Int J Mol Sci* 13: 142-172.
- 640 47. Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics - developing a new class of drugs.
641 *Nat Rev Drug Discov* 13: 759-780.

- 642 48. Lehmann AR (2003) DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome
643 and trichothiodystrophy. *Biochimie* 85: 1101-1111.
- 644 49. Garinis GA, Mitchell JR, Moorhouse MJ, Hanada K, de Waard H, et al. (2005) Transcriptome
645 analysis reveals cyclobutane pyrimidine dimers as a major source of UV-induced DNA breaks.
646 *EMBO J* 24: 3952-3962.
- 647 50. Mitchell DL (1988) The relative cytotoxicity of (6-4) photoproducts and cyclobutane dimers in
648 mammalian cells. *Photochem Photobiol* 48: 51-57.
- 649 51. Tornaletti S (2005) Transcription arrest at DNA damage sites. *Mutat Res* 577: 131-145.
- 650 52. Lo HL, Nakajima S, Ma L, Walter B, Yasui A, et al. (2005) Differential biologic effects of CPD and 6-
651 4PP UV-induced DNA damage on the induction of apoptosis and cell-cycle arrest. *BMC*
652 *Cancer* 5: 135.
- 653 53. Cleaver JE, Laposa RR, Limoli CL (2003) DNA replication in the face of (In)surmountable odds. *Cell*
654 *Cycle* 2: 310-315.
- 655 54. Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP (2010) Molecular mechanisms of ultraviolet
656 radiation-induced DNA damage and repair. *J Nucleic Acids* 2010: 592980.
- 657 55. Stewart ZA, Westfall MD, Pietenpol JA (2003) Cell-cycle dysregulation and anticancer therapy.
658 *Trends Pharmacol Sci* 24: 139-145.
- 659 56. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase
660 progression. *Genes Dev* 13: 1501-1512.
- 661 57. Elsayed YA, Sausville EA (2001) Selected novel anticancer treatments targeting cell signaling
662 proteins. *Oncologist* 6: 517-537.
- 663 58. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, et al. (2011) Nucleoside
664 modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase
665 resistance to cleavage by RNase L. *Nucleic Acids Res* 39: 9329-9338.

- 666 59. Einspahr JG, Alberts DS, Warneke JA, Bozzo P, Basye J, et al. (1999) Relationship of p53 mutations
667 to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis.
668 Neoplasia 1: 468-475.
- 669 60. Goukassian DA, Eller MS, Yaar M, Gilchrest BA (1999) Thymidine dinucleotide mimics the effect of
670 solar simulated irradiation on p53 and p53-regulated proteins. J Invest Dermatol 112: 25-31.
- 671 61. Humeniuk R, Rosu-Myles M, Fares J, Koller R, Bies J, et al. (2013) The role of tumor suppressor
672 p15Ink4b in the regulation of hematopoietic progenitor cell fate. *Blood Cancer J* 2: e99.
- 673 62. Humeniuk R, Koller R, Bies J, Aplan P, Wolff L (2014) Brief report: Loss of p15Ink4b accelerates
674 development of myeloid neoplasms in Nup98-HoxD13 transgenic mice. *Stem Cells* 32: 1361-
675 1366.
- 676 63. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk
677 inhibitors in human cancer. *Adv Cancer Res* 68: 67-108.
- 678 64. Soto Martinez JL, Cabrera Morales CM, Serrano Ortega S, Lopez-Nevot MA (2005) Mutation and
679 homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in
680 skin melanoma: p53, p21, p16 and p15. *Clin Transl Oncol* 7: 156-164.
- 681 65. Laud K, Marian C, Avril MF, Barrois M, Chompret A, et al. (2006) Comprehensive analysis of
682 CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to
683 be at heightened risk of melanoma. *J Med Genet* 43: 39-47.
- 684 66. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, et al. (2000) Analysis of G(1)/S checkpoint
685 regulators in metastatic melanoma. *Genes Chromosomes Cancer* 28: 404-414.
- 686 67. Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, et al. (2008) Genomic instability,
687 mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b),
688 p16(INK4a) and p53 in actinic keratosis. *Cancer Lett* 264: 145-161.
- 689 68. Jiao J, Mikulec C, Ishikawa TO, Magyar C, Dumlao DS, et al. (2014) Cell-type-specific roles for COX-
690 2 in UVB-induced skin cancer. *Carcinogenesis* 35: 1310-1319.

- 691 69. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in
692 cell proliferation and cell death in human malignancies. *Int J Cell Biol* 2010: 215158.
- 693 70. Vosooghi M, Amini M (2014) The discovery and development of cyclooxygenase-2 inhibitors as
694 potential anticancer therapies. *Expert Opin Drug Discov* 9: 255-267.
- 695 71. Berton TR, Pavone A, Fischer SM (2001) Ultraviolet-B irradiation alters the cell cycle machinery in
696 murine epidermis in vivo. *J Invest Dermatol* 117: 1171-1178.
- 697 72. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, et al. (2014) Cyclin E1 (CCNE1) as
698 independent positive prognostic factor in advanced stage serous ovarian cancer patients - a
699 study of the OVCAD consortium. *Eur J Cancer* 50: 99-110.
- 700 73. Hunt KK, Keyomarsi K (2005) Cyclin E as a prognostic and predictive marker in breast cancer.
701 *Semin Cancer Biol* 15: 319-326.
- 702 74. Xie JJ, Xie YM, Chen B, Pan F, Guo JC, et al. (2014) ATF3 functions as a novel tumor suppressor
703 with prognostic significance in esophageal squamous cell carcinoma. *Oncotarget* 5: 8569-
704 8582.
- 705 75. Kim YJ, Go H, Wu HG, Jeon YK, Park SW, et al. (2011) Immunohistochemical study identifying
706 prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy.
707 *Head Neck* 33: 1458-1466.
- 708 76. Ling F, Kang B, Sun XH (2014) Id proteins: small molecules, mighty regulators. *Curr Top Dev Biol*
709 110: 189-216.
- 710 77. Scheitz CJ, Tumbar T (2013) New insights into the role of Runx1 in epithelial stem cell biology and
711 pathology. *J Cell Biochem* 114: 985-993.
- 712 78. De Craene B, Denecker G, Vermassen P, Taminiau J, Mauch C, et al. (2014) Epidermal Snail
713 expression drives skin cancer initiation and progression through enhanced cytoprotection,
714 epidermal stem/progenitor cell expansion and enhanced metastatic potential. *Cell Death*
715 *Differ* 21: 310-320.

- 716 79. Bender K, Blattner C, Knebel A, Iordanov M, Herrlich P, et al. (1997) UV-induced signal
717 transduction. *J Photochem Photobiol B* 37: 1-17.
- 718 80. Gazel A, Banno T, Walsh R, Blumenberg M (2006) Inhibition of JNK promotes differentiation of
719 epidermal keratinocytes. *J Biol Chem* 281: 20530-20541.
- 720 81. Assefa Z, Garmyn M, Bouillon R, Merlevede W, Vandenheede JR, et al. (1997) Differential
721 stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor
722 in human keratinocytes. *J Invest Dermatol* 108: 886-891.
- 723 82. Adachi M, Gazel A, Pintucci G, Shuck A, Shifteh S, et al. (2003) Specificity in stress response:
724 epidermal keratinocytes exhibit specialized UV-responsive signal transduction pathways.
725 *DNA Cell Biol* 22: 665-677.
- 726 83. Zhang JY, Green CL, Tao S, Khavari PA (2004) NF-kappaB RelA opposes epidermal proliferation
727 driven by TNFR1 and JNK. *Genes Dev* 18: 17-22.
- 728 84. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, et al. (2002) Extracellular
729 regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. *J*
730 *Dermatol Sci* 30: 94-99.
- 731 85. Koehler K, Mielke K, Schunck M, Neumann C, Herdegen T, et al. (2011) Distinct roles of JNK-1 and
732 ERK-2 isoforms in permeability barrier repair and wound healing. *Eur J Cell Biol* 90: 565-571.
- 733 86. Zhang JY, Selim MA (2012) The role of the c-Jun N-terminal Kinase signaling pathway in skin
734 cancer. *Am J Cancer Res* 2: 691-698.
- 735 87. Quan T, He T, Voorhees JJ, Fisher GJ (2005) Ultraviolet irradiation induces Smad7 via induction of
736 transcription factor AP-1 in human skin fibroblasts. *J Biol Chem* 280: 8079-8085.
- 737 88. Holbrook NJ, Fornace AJ, Jr. (1991) Response to adversity: molecular control of gene activation
738 following genotoxic stress. *New Biol* 3: 825-833.

Figure legends

Figure 1. Accelerated photorepair of CPDs in HaCaT cells transfected with CPD-PL Ψ -mRNA. HaCaT cells were transfected with lipofectamine-complexed Ψ -mRNA encoding CPD-photolyase. Twelve hours later, cells were subjected to 20 mJ/cm² UVB and immediately exposed to photoreactivating light (photoreactivated) or left in the dark (non-photoreactivated) for 1 h and then maintained at 37°C for 5 and 23 h. After incubation at 5 and 23 h, genomic DNA was isolated at the indicated times after UVB irradiation and the amount of CPDs was measured by ELISA. The values were calculated relative to those obtained with cells that were not UVB-irradiated. Significance was assessed by unpaired, two-sample *t*-test, *p*<0.05. Error bars represent the standard error of the mean from three experiments performed independently.

Figure 2. Experimental verification of microarray results for 9 selected genes. HaCaT cells were exposed to 20 mJ/cm² UVB at 12 h after delivery of CPD-PL Ψ -mRNA. Immediately thereafter, cells were either subjected to photoreactivating light (active CPD-photolyase) or left in the dark (inactive CPD-photolyase) for 1 h. Following incubation total RNA was extracted at 5 and 23 h, then real-time RT-qPCR was performed to validate the CPD-dependent expression of ATF3, CCNE1, CDKN2B, EGR1, ID2, PTGS2, RUNX1, SNAI1 and SNAI2. Values measured in UVB irradiated cells with or without photoreactivation were related to those measured in non-UVB irradiated cells that were transfected control Ψ -mRNA, (pecked lines). Asterisks indicate significant differences (two-tailed, unpaired *t*-test; *p*<0.05) between photoreactivated (active CPD-photolyase) and non-photoreactivated (inactive CPD-photolyase) samples. The results of RT-qPCR are means \pm SEM from three independent experiments in triplicate.

Figure 3. Photorepair of CPDs prevents altered expression of cyclin E1 and p15INK4b protein in UVB irradiated HaCaT cells. Cells were transfected with lipofectamine-

complexed CPD-PL Ψ -mRNA, 12 h later irradiated with 20 mJ/cm² UVB and immediately exposed to photoreactivating light (active CPD-photolyase) or kept in the dark (inactive CPD-photolyase) for 1 h. Subsequently, cells were cultured at 37°C until harvested at the indicated time after UVB irradiation. (A) The expression of cyclin E1 and p15INK4b were analyzed by Western blot. (B) Quantitation of western blots displays relative changes in protein expression normalized to β -actin. Pixel densities were calculated relative to those obtained with cells that were not UVB irradiated (pecked lines). Significance was assessed by two-tailed, unpaired *t*-test (asterisk, $p < 0.05$) showing differences between photoreactivated and non-photoreactivated samples. Error bars represent the standard error of the mean. The results are means of three independent experiments.

Figure 4. Induction of cyclin E1 and p15INK4b protein expression upon UVB exposure is regulated through the JNK signalling pathway in HaCaT cells. Keratinocytes transfected with CPD-PL Ψ -mRNA were incubated in serum-free medium supplemented with JNK inhibitor (SP600125) for 1 h. Immediately thereafter, cells were irradiated with a physiological dose of UVB or left untreated followed by exposure to photoreactivating light (or not) for 1 h. The cells were cultured further in serum-free medium supplemented with the inhibitor. Cells were harvested for western blot assay at the indicated time. Protein levels of cyclin E1, p15INK4b, and β -actin are noted. The figure shows representative results from three independent experiments.

Supporting information

S1 Table. List of all up and downregulated genes related to CPD lesions determined in CPD-PL Ψ -mRNA transfected human keratinocytes at 6 h after UVB exposure by microarray analyses.

S2 Table. List of all up and downregulated genes related to CPD lesions determined in CPD-PL Ψ -mRNA transfected human keratinocytes at 24 h after UVB exposure by microarray analyses.

S1 Fig. Divergence of UVB-mediated gene expression changes using CPD-specific photolyase encoded by *in vitro*-transcribed mRNA. To characterize the expression profile of CPD-related genes, oligonucleotide microarray was carried out as described in Materials and Methods. Bar graph represents the total number of UVB-responsive genes determined 6 and 24 h after the exposure. Bioset was divided into CPD-independent (the presence of active photolyase had no effect on the expression level of genes modified by UVB irradiation) and CPD-dependent (the presence of active photolyase has restored the expression level of genes modified by UVB irradiation) genes. Cut-off values for changes in gene expression were set at ± 2 -fold.

S2 Fig. Top network interactions among CPD-dependent genes determined at 6 and 24 h after UVB irradiation in CPD-PL Ψ -mRNA transfected keratinocytes. To analyze network interactions of CPD-dependent genes, datasets representing differentially regulated genes derived from microarray were imported into the Ingenuity Pathway Analysis (IPA) application. The list of the top three networks and associated cellular functions of all CPD-related gene datasets are shown with their respective scores and *p*-values ($p < 0.05$) obtained from IPA (panel A). The score is derived from a *p*-value and indicates the likelihood of the focus genes in a network being found together due to random chance (defined as: $-\log_{10}(\text{p-value})$). The most highly rated networks of genes, determined 6 (panel B) and 24 h (panel C) after UVB irradiation, are illustrated with the significantly up- (red shaded) and downregulated (green shaded) genes modulated in a CPD-dependent manner. Genes in empty nodes were not identified as differentially expressed in our experiment and were generated

automatically by IPA Knowledge Base indicating a relevance to this network. The genes marked with blue circle have been validated by RT-qPCR.

S3 Fig. Functional classification of CPD-related genes belonging to top rated networks

determined by IPA. To analyze functional classification of CPD-responsive genes belonging to top networks, datasets derived from the results of network analysis were imported into the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool. The list of these CPD-dependent genes, determined at 6 and 24 h after UVB irradiation is shown according to their cellular functions (panel A-G). Gene expression values measured in photolyase mRNA transfected and UVB irradiated cells (PL+UVB) were compared to those measured in non-UVB irradiated control cells, while photolyase mRNA transfected, UVB-irradiated and photoreactivated samples (active CPD-photolyase) were compared to those that were photolyase mRNA transfected and UVB irradiated, but left without photoreactivation (inactive CPD-photolyase). Cut-off values for changes in gene expression were set at ± 2 -fold. To evaluate statistical analysis unpaired, Student's *t*-test followed by Benjamini-Hochberg corrections were used. The genes marked with red boxes were selected for further investigation. The blue box in (F) represents a gene (IL6) that was confirmed in previous work [19] to have CPD-dependent changes in expression.

Responses to the comments of Reviewer 1

Dear Reviewer,

Thank you for your thoughtful and constructive comments.

We addressed all your comments and further experimentation was performed, according to your advice.

Specifically:

Comment 1. The paper would be much strengthened by further experiments directly addressing JNK in mediating CPD effects (e.g. inhibit JNK and then determine photolyase effect with and without UV), without this critical experiment, the manuscript is, in my opinion, too correlative.

We agree with your assertion and carried out the proposed experiment. The results are included into the revised Figure 4 (see lines 330-340, on page 15 of the revised manuscript).

Comment 2. Is it possible that certain genes (e.g. their promoters or enhancers) may be particularly vulnerable to UV-induced CPD formation? If so, then these genes may be down-regulated directly by UV rather than through a damage-response pathway such as JNK. (alternatively a gene's expression might be upregulated if an inhibitory gene's expression were CPD-prone).

We agree that regulatory regions of selected genes might be directly vulnerable to UVB, therefore we included this potential in the manuscript and added background material to the revised manuscript and propounded an experimental procedure to appropriately support this issue (see lines 483-491, on pages 21-22 of the revised manuscript).

Comment 3. It seems odd that the figure legends are embedded right in the text rather than as a separate section.

We corrected this error. The figure legends are now in a separate section at the end of the revised manuscript.

Comment 4. Do the data exclude a role for gene regulation by 6,4-photoproducts?

We have added a new section to the revised manuscript in which we provide additional information related to the contribution of 6-4 photoproducts to UVB-induced changes of gene expression (see lines 368-379, on page 17 of the revised manuscript).

Comment 5. The role of p53 should also be examined in CPD-induced gene expression changes.

We agree, so we have inserted background material to provide additional information about the role of p53 in UVB-induced cellular stress responses (see lines 395-404, on page 18 of the revised manuscript).

Response to the comment of Reviewer 2

Dear Reviewer,

We appreciate your comment and following your suggestion we prepared a separate conclusion section.

Comment 1. The major short-coming, which is mostly editorial, is coming from the lack of a separate conclusion section. The last paragraph, which effectively serves as a conclusion, needs to be expanded and be placed in line with the abstract.

We have added a separate conclusion section to provide additional context to the revised manuscript (see lines 493-511, on page 22 of the revised manuscript).